US5534617A
(en)
*
|
1988-10-28 |
1996-07-09 |
Genentech, Inc. |
Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
|
US5688666A
(en)
*
|
1988-10-28 |
1997-11-18 |
Genentech, Inc. |
Growth hormone variants with altered binding properties
|
US5350836A
(en)
*
|
1989-10-12 |
1994-09-27 |
Ohio University |
Growth hormone antagonists
|
US5723286A
(en)
*
|
1990-06-20 |
1998-03-03 |
Affymax Technologies N.V. |
Peptide library and screening systems
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
DE69129154T2
(de)
*
|
1990-12-03 |
1998-08-20 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
AU662148B2
(en)
|
1991-04-10 |
1995-08-24 |
Scripps Research Institute, The |
Heterodimeric receptor libraries using phagemids
|
US5506107A
(en)
|
1991-05-10 |
1996-04-09 |
Genentech, Inc. |
Selecting ligand agonists and antagonists
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
EP0590058B1
(de)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
Humanisierter Heregulin Antikörper
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
DE4122599C2
(de)
*
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5270170A
(en)
*
|
1991-10-16 |
1993-12-14 |
Affymax Technologies N.V. |
Peptide library and screening method
|
US5733731A
(en)
*
|
1991-10-16 |
1998-03-31 |
Affymax Technologies N.V. |
Peptide library and screening method
|
WO1993011236A1
(en)
|
1991-12-02 |
1993-06-10 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5849535A
(en)
*
|
1995-09-21 |
1998-12-15 |
Genentech, Inc. |
Human growth hormone variants
|
US5874400A
(en)
|
1993-07-26 |
1999-02-23 |
Cor Therapeutics |
Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
|
EP0741783B1
(de)
|
1993-12-30 |
2009-03-18 |
President And Fellows Of Harvard College |
"hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
|
US6406855B1
(en)
|
1994-02-17 |
2002-06-18 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US5837458A
(en)
*
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6335160B1
(en)
*
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6335319B1
(en)
*
|
1994-11-15 |
2002-01-01 |
Metabolic Pharmaceuticals, Inc. |
Treatment of obesity
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6475806B1
(en)
|
1995-06-07 |
2002-11-05 |
Praecis Pharmaceuticals, Inc. |
Anchor libraries and identification of peptide binding sequences
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
ES2203722T3
(es)
*
|
1995-11-10 |
2004-04-16 |
Elan Corporation, Plc |
Peptidos que faccilitan el transporte a traves de tejidos y metodos de identificarlos y usarlos.
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
WO1997035194A2
(en)
*
|
1996-03-21 |
1997-09-25 |
President And Fellows Of Harvard College |
Enantiomeric screening process, and compositions therefor
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6361938B1
(en)
|
1996-11-08 |
2002-03-26 |
Elan Corporation, Plc |
Peptides which enhance transport across tissues and methods of identifying and using the same
|
US20070185032A1
(en)
*
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6497874B1
(en)
|
1997-02-05 |
2002-12-24 |
Maardh Sven |
Recombinant phages
|
US6403764B1
(en)
|
1999-01-06 |
2002-06-11 |
Genentech, Inc. |
Insulin-like growth factor-1 protein variants
|
AU7137398A
(en)
|
1997-04-16 |
1998-11-11 |
Millennium Pharmaceuticals, Inc. |
Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
|
US6306826B1
(en)
|
1997-06-04 |
2001-10-23 |
The Regents Of The University Of California |
Treatment of heart failure with growth hormone
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US6639050B1
(en)
|
1997-07-21 |
2003-10-28 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
US7378506B2
(en)
|
1997-07-21 |
2008-05-27 |
Ohio University |
Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
|
WO1999006587A2
(en)
|
1997-08-01 |
1999-02-11 |
Morphosys Ag |
Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
|
GB9723955D0
(en)
|
1997-11-14 |
1998-01-07 |
Generic Biolog Limited |
Improvements in or relating to detection of molecules in samples
|
GB2334580B
(en)
*
|
1997-11-14 |
2002-12-18 |
Generic Biolog Ltd |
Improvements in or relating to detection of exogenously administered polypeptides
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
DK1481989T3
(da)
|
1997-11-21 |
2008-08-25 |
Genentech Inc |
A-33-beslægtede antigener og deres farmakologiske anvendelser
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
US7163682B2
(en)
|
1998-04-13 |
2007-01-16 |
The Forsyth Institute |
Glucan binding protein and glucosyltransferase immunogens
|
US7056517B2
(en)
|
1998-04-13 |
2006-06-06 |
The Forsyth Institute |
Glucosyltransferase immunogens
|
AU5122499A
(en)
|
1998-07-27 |
2000-02-21 |
Genentech Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
US6387888B1
(en)
|
1998-09-30 |
2002-05-14 |
American Foundation For Biological Research, Inc. |
Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
|
US6485972B1
(en)
|
1998-10-15 |
2002-11-26 |
President And Fellows Of Harvard College |
WNT signalling in reproductive organs
|
US6420110B1
(en)
|
1998-10-19 |
2002-07-16 |
Gpc Biotech, Inc. |
Methods and reagents for isolating biologically active peptides
|
ES2316194T3
(es)
*
|
1998-10-28 |
2009-04-01 |
Cornell Research Foundation, Inc. |
Metodos para la regulacion de la angiogenesis y la integridad vascular utilizando los ligandos bdnf, nt-3 y nt-4.
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
US6696063B1
(en)
*
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
EP1141314A2
(de)
*
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Für antigene polypeptide des hiv type c kodierende polynukleotide, entsprechende polypeptide und verwendungen davon
|
ATE384795T1
(de)
*
|
1998-12-31 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Modifizierte hiv env polypeptide
|
US7935805B1
(en)
*
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
WO2000039302A2
(en)
*
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
JP2002535967A
(ja)
*
|
1999-01-06 |
2002-10-29 |
ジェネンテック・インコーポレーテッド |
インシュリン様成長因子(igf)i変異体
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
EP2301947A3
(de)
|
1999-02-26 |
2011-11-23 |
Millennium Pharmaceuticals, Inc. |
Sekretierte Proteine und Verwendungen dafür
|
AU767066B2
(en)
|
1999-03-03 |
2003-10-30 |
Curis, Inc. |
Methods of modulating lipid metabolism and storage
|
DK2168984T3
(da)
|
1999-03-25 |
2012-12-10 |
Abbott Gmbh & Co Kg |
Humane antistoffer, som binder humant IL-12, og fremgangsmåder til pro-duktion heraf
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
WO2000058521A2
(en)
*
|
1999-03-31 |
2000-10-05 |
Rosetta Inpharmatics, Inc. |
Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US6994982B1
(en)
*
|
1999-05-05 |
2006-02-07 |
Phylogica Limited |
Isolating biological modulators from biodiverse gene fragment libraries
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
US7270969B2
(en)
*
|
1999-05-05 |
2007-09-18 |
Phylogica Limited |
Methods of constructing and screening diverse expression libraries
|
US6197517B1
(en)
|
1999-05-21 |
2001-03-06 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6200803B1
(en)
|
1999-05-21 |
2001-03-13 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
US6221597B1
(en)
|
1999-05-21 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US20030166003A1
(en)
*
|
1999-06-14 |
2003-09-04 |
Cochran Andrea G. |
Structured peptide scaffold for displaying turn libraries on phage
|
ATE296350T1
(de)
|
1999-06-14 |
2005-06-15 |
Genentech Inc |
Strukturiertes peptidgerüst zur ausstellung von drehung-bibliotheken auf phage
|
US20040001826A1
(en)
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
JP4312403B2
(ja)
|
1999-07-20 |
2009-08-12 |
モルフォシス・アクチェンゲゼルシャフト |
(ポリ)ペプチド/タンパク質を、ジスルフィド結合を介してバクテリオファージ粒子に表示させる新規方法
|
JP4896327B2
(ja)
|
1999-08-23 |
2012-03-14 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
Pd−1、b7−4の受容体、およびその使用
|
DE19943743C2
(de)
*
|
1999-09-03 |
2002-02-07 |
Jerini Biotools Gmbh |
Verfahren zur Identifizierung von Bindungspartnern mit positions-spezifischen Arrays
|
JP4931310B2
(ja)
*
|
1999-10-20 |
2012-05-16 |
ジェネンテック, インコーポレイテッド |
ヘルパーt細胞性疾患の治療のためのt細胞分化の調節
|
US20060073509A1
(en)
*
|
1999-11-18 |
2006-04-06 |
Michael Kilpatrick |
Method for detecting and quantitating multiple subcellular components
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
AU784983B2
(en)
*
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
US20020004247A1
(en)
*
|
1999-12-23 |
2002-01-10 |
Genentech, Inc. |
Assay method
|
AU784883B2
(en)
|
1999-12-30 |
2006-07-20 |
President And Fellows Of Harvard College |
Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
CN102504024A
(zh)
|
2000-02-10 |
2012-06-20 |
雅培制药有限公司 |
结合人白介素-18的抗体及制备和使用方法
|
US6436677B1
(en)
|
2000-03-02 |
2002-08-20 |
Promega Corporation |
Method of reverse transcription
|
US6632645B1
(en)
|
2000-03-02 |
2003-10-14 |
Promega Corporation |
Thermophilic DNA polymerases from Thermoactinomyces vulgaris
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
JP2003530839A
(ja)
|
2000-04-12 |
2003-10-21 |
プリンシピア ファーマスーティカル コーポレイション |
アルブミン融合タンパク質
|
ES2393535T3
(es)
*
|
2000-04-17 |
2012-12-26 |
Dyax Corp. |
Nuevos métodos para construir bibliotecas de paquetes genéticos que presentan de forma colectiva los miembros de una familia diversa de péptidos, polipéptidos o proteínas
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
US7495070B2
(en)
*
|
2000-04-24 |
2009-02-24 |
Yale University |
Protein binding miniature proteins
|
CA2407377A1
(en)
*
|
2000-04-24 |
2001-11-01 |
Yale University |
Dna & protein binding miniature proteins
|
WO2001087323A2
(en)
|
2000-05-16 |
2001-11-22 |
Genentech, Inc. |
Method for treating cartilage disorders
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US6573370B1
(en)
|
2000-05-19 |
2003-06-03 |
Regents Of The University Of Michigan |
PON3 and uses thereof
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
ATE459367T1
(de)
|
2000-06-08 |
2010-03-15 |
Immune Disease Inst Inc |
Methoden und verbindungen zur hemmung immunoglobulin-vermittelter reperfusions- verletzungen
|
EP1294949A4
(de)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Menschlicher tumornekrosefaktor delta und epsilon
|
PT2275449T
(pt)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
EP1299094A2
(de)
*
|
2000-06-28 |
2003-04-09 |
Bristol-Myers Squibb Company |
Selektive androgenrezeptormodulatoren und methoden zu deren identifizierung, entwurf und verwendung
|
NZ522844A
(en)
|
2000-06-28 |
2005-02-25 |
Brigham & Womens Hospital |
PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
|
CZ2003291A3
(cs)
|
2000-06-29 |
2003-05-14 |
Abbott Laboratories |
Duálně specifické protilátky a způsoby jejich výroby a použití
|
US7176037B2
(en)
*
|
2000-07-13 |
2007-02-13 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US6951947B2
(en)
*
|
2000-07-13 |
2005-10-04 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US7807872B2
(en)
|
2000-07-14 |
2010-10-05 |
Cropdesign N.V. |
Down regulation of plant cyclin-dependent kinase inhibitors
|
US6878861B2
(en)
|
2000-07-21 |
2005-04-12 |
Washington State University Research Foundation |
Acyl coenzyme A thioesterases
|
EP2014303A2
(de)
|
2000-07-27 |
2009-01-14 |
Genentech, Inc. |
APO-2L-Rezeptorantagonisten und CPT-11-Synergismus
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
EP1309312A2
(de)
*
|
2000-08-07 |
2003-05-14 |
Inhale Therapeutic Systems, Inc. |
Inhalierbare sprühgetrocknete pulver aus proteinen die bündel aus 4 helices ausbilden mit minimierter aggregation
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
ES2387537T3
(es)
*
|
2000-09-13 |
2012-09-25 |
Glaxosmithkline Llc |
Composiciones farmacéuticas para la administración sostenida de péptidos
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
EP1366078B1
(de)
|
2000-09-26 |
2008-07-30 |
Genentech, Inc. |
Antagonisten des ige-rezeptors
|
US7393532B1
(en)
|
2000-10-18 |
2008-07-01 |
Genentech, Inc. |
Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
|
US6673580B2
(en)
*
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US6841359B2
(en)
|
2000-10-31 |
2005-01-11 |
The General Hospital Corporation |
Streptavidin-binding peptides and uses thereof
|
WO2002046208A2
(en)
|
2000-11-01 |
2002-06-13 |
Elusys Therapeutics, Inc. |
Method of producing biospecific molecules by protein trans-splicing
|
IL155951A0
(en)
|
2000-11-28 |
2003-12-23 |
Wyeth Corp |
Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
PL365605A1
(en)
|
2000-11-28 |
2005-01-10 |
Wyeth |
Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
ATE414720T1
(de)
|
2000-12-05 |
2008-12-15 |
Alexion Pharma Inc |
Rationell entworfene antikörper
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
AU2002246632B2
(en)
*
|
2000-12-08 |
2007-04-05 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US9249229B2
(en)
*
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20040198661A1
(en)
*
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
*
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
EP2357187A1
(de)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
ES2430857T3
(es)
|
2000-12-18 |
2013-11-22 |
Dyax Corp. |
Bibliotecas focalizadas de paquetes genéticos
|
WO2002051870A2
(en)
*
|
2000-12-22 |
2002-07-04 |
GRAD, Carole Legal Representative of KAPLAN, Howard |
Phage display libraries of human vh fragments
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
PE20020801A1
(es)
|
2001-01-05 |
2002-09-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
WO2008048300A2
(en)
|
2005-11-30 |
2008-04-24 |
Massachusetts Institute Of Technology |
Pathogen detection biosensor
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
US7323327B2
(en)
|
2001-02-23 |
2008-01-29 |
Dsm Ip Assets B.V. |
Genes encoding novel proteolytic enzymes
|
US20030068320A1
(en)
*
|
2001-03-02 |
2003-04-10 |
Christine Dingivan |
Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
DE60239097D1
(de)
|
2001-03-02 |
2011-03-17 |
Gpc Biotech Ag |
Drei-hybrid-assaysystem
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2342376C
(en)
*
|
2001-03-20 |
2013-11-12 |
Marco Colonna |
A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
JP2005508608A
(ja)
|
2001-03-22 |
2005-04-07 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
問題遺伝子に対して特異的な抗体を発現するトランスジェニック動物及びその使用
|
WO2002079499A1
(en)
|
2001-04-02 |
2002-10-10 |
Wyeth |
Pd-1, a receptor for b7-4, and uses therefor
|
WO2002083704A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP2277897A1
(de)
|
2001-04-16 |
2011-01-26 |
Wyeth Holdings Corporation |
Polypeptideantigene codierende offene Leseraster aus Streptococcus pneumoniae und Verwendungen davon
|
US6914123B2
(en)
|
2001-04-17 |
2005-07-05 |
Genentech, Inc. |
Hairpin peptides with a novel structural motif and methods relating thereto
|
US7244853B2
(en)
|
2001-05-09 |
2007-07-17 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
NZ529359A
(en)
|
2001-05-25 |
2007-04-27 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer
|
WO2002098280A2
(en)
*
|
2001-06-04 |
2002-12-12 |
Ikonisys Inc. |
Method for detecting infectious agents using computer controlled automated image analysis
|
US20030148380A1
(en)
*
|
2001-06-05 |
2003-08-07 |
Belcher Angela M. |
Molecular recognition of materials
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20050164515A9
(en)
*
|
2001-06-05 |
2005-07-28 |
Belcher Angela M. |
Biological control of nanoparticle nucleation, shape and crystal phase
|
US20030113714A1
(en)
*
|
2001-09-28 |
2003-06-19 |
Belcher Angela M. |
Biological control of nanoparticles
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
CA2633595A1
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2270185A3
(de)
|
2001-06-22 |
2012-04-04 |
Pioneer Hi-Bred International, Inc. |
Defensinpolynucleotide und Verfahren zu ihrer Verwendung
|
JP5033303B2
(ja)
|
2001-07-05 |
2012-09-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
|
EP2292772A1
(de)
*
|
2001-07-05 |
2011-03-09 |
Novartis Vaccines and Diagnostics, Inc. |
HIV Impfung mit für ein HIV Polypeptid kodierender DNS und einem HIV Polypeptid
|
DE10135039C1
(de)
*
|
2001-07-18 |
2003-03-13 |
Nemod Immuntherapie Ag |
Verfahren zur Isolierung großer Varianzen spezifischer Moleküle für ein Zielmolekül aus Phagemid-Gen-Bibliotheken
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
KR100458083B1
(ko)
*
|
2001-08-29 |
2004-11-18 |
주식회사 아이지세라피 |
파아지 디스플레이 라이브러리로부터 특정 이종 단백질의효율적인 분리를 위한 개선된 헬퍼 파아지 시스템
|
JP2005521380A
(ja)
*
|
2001-08-31 |
2005-07-21 |
カイロン コーポレイション |
抗原性b型hivポリペプチドをコードするポリヌクレオチド、そのポリペプチドおよびそれらの使用
|
US20030170614A1
(en)
*
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
JP4360906B2
(ja)
*
|
2001-09-14 |
2009-11-11 |
サイトス バイオテクノロジー アーゲー |
ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
ATE486092T1
(de)
|
2001-09-18 |
2010-11-15 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
US20030073104A1
(en)
*
|
2001-10-02 |
2003-04-17 |
Belcher Angela M. |
Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US7858297B2
(en)
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
US7572886B2
(en)
|
2001-12-18 |
2009-08-11 |
Centre National De La Recherche Scientifique |
Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
|
US7087418B2
(en)
|
2001-12-19 |
2006-08-08 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
EP2261250B1
(de)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin Fusionsproteine
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
EP1461001A4
(de)
*
|
2002-01-03 |
2010-03-31 |
Scripps Research Inst |
Mit krebs assoziiertes epitop
|
EP1534739A4
(de)
*
|
2002-01-18 |
2006-05-31 |
Bristol Myers Squibb Co |
Identifizierung von polynukleotiden und polypeptid zur vorhersage der aktivität von verbindungen, die mit protein-tyrosinkinasen und/oder protein-tyrosinkinasewegen wechselwirken
|
WO2003104428A2
(en)
*
|
2002-01-21 |
2003-12-18 |
Vaccinex, Inc. |
Gene differentially expressed in breast and bladder cancer and encoded polypeptides
|
US7094579B2
(en)
|
2002-02-13 |
2006-08-22 |
Xoma Technology Ltd. |
Eukaryotic signal sequences for prokaryotic expression
|
DE60329020D1
(de)
|
2002-03-01 |
2009-10-08 |
Siemens Healthcare Diagnostics |
Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von körperflüssigkeiten
|
AU2003213594A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Bayer Corporation |
Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
|
EP1572149A2
(de)
|
2002-03-07 |
2005-09-14 |
The Forsyth Institute |
Immunogenität von glucan-bindungsprotein
|
CA2480052A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
US7745192B2
(en)
|
2002-04-03 |
2010-06-29 |
Venomics Pty Limited |
Prothrombin activating protein
|
EP2270049A3
(de)
|
2002-04-12 |
2011-03-09 |
Medimmune, Inc. |
Rekombinante Anti-Interleukin-9-Antikörper
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
EA008607B1
(ru)
|
2002-05-21 |
2007-06-29 |
ДСМ Ай Пи ЭССЕТС Б.В. |
Полинуклеотид, кодирующий фосфолипазу aspergillus niger, фосфолипаза aspergillus niger и способы получения и применения полинуклеотида и фосфолипазы
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
CA2488441C
(en)
*
|
2002-06-03 |
2015-01-27 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
EP1558086A4
(de)
*
|
2002-06-14 |
2008-03-05 |
Univ Case Western Reserve |
Zelltargeting-verfahren und zusammensetzungen
|
US7667099B2
(en)
|
2002-06-20 |
2010-02-23 |
Board Of Trustees Of Michigan State University |
Plastid division and related genes and proteins, and methods of use
|
ES2442615T5
(es)
|
2002-07-18 |
2023-03-16 |
Merus Nv |
Producción recombinante de mezclas de anticuerpos
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US20040219142A1
(en)
|
2002-07-19 |
2004-11-04 |
Abbott Laboratories S.A. |
Treatment of skin and nail disorders using TNFalpha inhibitors
|
US7250551B2
(en)
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
JP2005535329A
(ja)
|
2002-08-10 |
2005-11-24 |
イェール ユニバーシティ |
Nogo受容体アンタゴニスト
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
CA2495198C
(en)
|
2002-08-19 |
2014-03-11 |
Dsm Ip Assets B.V. |
Novel lipases and uses thereof
|
DE10238846A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Nemod Immuntherapie Ag |
Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
|
ATE519862T1
(de)
|
2002-08-20 |
2011-08-15 |
Millennium Pharm Inc |
Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
|
WO2004018505A1
(en)
|
2002-08-20 |
2004-03-04 |
Yeda Research And Development Co. Ltd. |
Akap84 and its use for visualization of biological structures
|
KR20050057047A
(ko)
*
|
2002-08-29 |
2005-06-16 |
제넨테크, 인크. |
아캐트-스큐트 유사-2 폴리펩티드 및 코딩 핵산 및 종양의진단 및 치료 방법
|
WO2004021994A2
(en)
|
2002-09-04 |
2004-03-18 |
Biopolymer Engineering, Inc. |
Cancer therapy using whole glucan particles and antibodies
|
ATE466085T1
(de)
*
|
2002-09-09 |
2010-05-15 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
US20050064508A1
(en)
|
2003-09-22 |
2005-03-24 |
Semzyme |
Peptide mediated synthesis of metallic and magnetic materials
|
ZA200502612B
(en)
|
2002-10-08 |
2007-07-25 |
Rinat Neuroscience Corp |
Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
|
WO2005000194A2
(en)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
US20040146512A1
(en)
*
|
2002-10-09 |
2004-07-29 |
Arnon Rosenthal |
Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
|
EP2298806A1
(de)
|
2002-10-16 |
2011-03-23 |
Purdue Pharma L.P. |
Antikörper, die an zellassoziiertes CA 125/0722P binden, und Verfahren zu deren Anwendung
|
WO2004050683A2
(en)
*
|
2002-12-02 |
2004-06-17 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
US7056702B2
(en)
*
|
2002-12-16 |
2006-06-06 |
Kimberly Clark Co |
Detecting lipocalin
|
CA2511295A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Rinat Neuroscience Corp. |
Methods for treating taxol-induced sensory neuropathy
|
AU2003293958A1
(en)
*
|
2002-12-23 |
2004-07-22 |
Apalexo Biotechnologie Gmbh |
Purification of recombinant filamental bacteriophages by means of affinity chromatography to increase the immunogenicity and efficacy of phagic vaccines
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
EP1575517B1
(de)
|
2002-12-24 |
2012-04-11 |
Rinat Neuroscience Corp. |
Anti-ngf-antikörper und verfahren zu ihrer verwendung
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
DE602004031589D1
(de)
|
2003-01-07 |
2011-04-14 |
Dyax Corp |
Kunitz-domäne-bibliothek
|
AU2004205631A1
(en)
*
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004065551A2
(en)
*
|
2003-01-21 |
2004-08-05 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
WO2004072232A2
(en)
|
2003-01-31 |
2004-08-26 |
Promega Corporation |
Covalent tethering of functional groups to proteins
|
US7429472B2
(en)
*
|
2003-01-31 |
2008-09-30 |
Promega Corporation |
Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
|
CN102993306B
(zh)
*
|
2003-02-01 |
2015-01-28 |
唐纳士公司 |
高亲和力抗人类IgE抗体
|
DE602004030535D1
(de)
|
2003-02-19 |
2011-01-27 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
PL378582A1
(pl)
|
2003-03-19 |
2006-05-02 |
Biogen Idec Ma Inc. |
Białko wiążące receptor Nogo
|
EP1620127A4
(de)
*
|
2003-03-20 |
2007-04-04 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von taxol-induzierten darmstörungen
|
US7294701B2
(en)
*
|
2003-04-02 |
2007-11-13 |
Technion Research & Development Foundation Ltd. |
Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
|
CA2521826C
(en)
|
2003-04-11 |
2013-08-06 |
Jennifer L. Reed |
Recombinant il-9 antibodies and uses thereof
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
CN101274098A
(zh)
|
2003-05-30 |
2008-10-01 |
健泰科生物技术公司 |
利用抗-vegf抗体的治疗
|
PL1636593T3
(pl)
|
2003-06-06 |
2009-08-31 |
Genentech Inc |
Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
|
EP2481814A3
(de)
*
|
2003-06-09 |
2012-10-10 |
The Regents of the University of Michigan |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Krebs
|
AU2004255557B2
(en)
|
2003-06-09 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
MX341074B
(es)
|
2003-07-08 |
2016-08-05 |
Genentech Inc |
Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
|
JP2008500005A
(ja)
*
|
2003-07-15 |
2008-01-10 |
バロス リサーチ インスティテュート |
癌及び感染症の免疫療法のための組成物及び方法
|
US20050058658A1
(en)
*
|
2003-07-15 |
2005-03-17 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
US7758859B2
(en)
*
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
AU2004263896A1
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
ES2458636T3
(es)
|
2003-08-18 |
2014-05-06 |
Medimmune, Llc |
Humanización de anticuerpos
|
EP1668026A1
(de)
*
|
2003-09-05 |
2006-06-14 |
The Scripps Research Institute |
Nachweis von cholesterin-ozonierungsprodukten
|
US20050085557A1
(en)
|
2003-09-05 |
2005-04-21 |
Paul Wentworth |
Therapeutic procedures
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CN102517381A
(zh)
|
2003-10-07 |
2012-06-27 |
千年药品公司 |
用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
DK1677735T3
(da)
|
2003-10-17 |
2014-10-27 |
Joslin Diabetes Center Inc |
Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
|
US7329725B1
(en)
*
|
2003-10-29 |
2008-02-12 |
Nastech Pharmaceutical Company Inc. |
Phage displayed Trp cage ligands
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
CA2546285C
(en)
|
2003-11-17 |
2015-12-29 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
AU2004292393C1
(en)
*
|
2003-11-21 |
2011-08-04 |
Ucb Pharma S.A. |
Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
|
NZ547591A
(en)
*
|
2003-12-04 |
2009-11-27 |
Vaccinex Inc |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
CA2548282A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
WO2005062955A2
(en)
*
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
GB0329825D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
CN1956738B
(zh)
|
2004-01-09 |
2013-05-29 |
辉瑞大药厂 |
MAdCAM抗体
|
WO2005069845A2
(en)
|
2004-01-14 |
2005-08-04 |
Ohio University |
Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
|
US7981843B2
(en)
|
2004-01-20 |
2011-07-19 |
Kalobios Pharmaceuticals, Inc. |
Antibody specificity transfer using minimal essential binding determinants
|
CA2554054C
(en)
|
2004-01-20 |
2013-06-04 |
Merus B.V. |
Mixtures of binding proteins
|
BRPI0506864A
(pt)
|
2004-01-21 |
2007-05-29 |
Novo Nordisk As |
método para conjugar peptìdeos, peptìdeo conjugado, composto e sais, pró-drogas e solvatos farmaceuticamente aceitáveis destes, composição farmacêutica, uso de um composto, e, método para tratamento de doença
|
WO2005072341A2
(en)
|
2004-01-21 |
2005-08-11 |
Fujirebio America, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
|
GB2429207A
(en)
*
|
2004-02-02 |
2007-02-21 |
Ambrx Inc |
Modified human interferon polypeptides and their uses
|
CA2554779A1
(en)
*
|
2004-02-03 |
2005-08-18 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
SI1729795T1
(sl)
|
2004-02-09 |
2016-04-29 |
Human Genome Sciences, Inc. |
Albuminski fuzijski proteini
|
EP2168986A3
(de)
|
2004-02-19 |
2010-07-28 |
Genentech, Inc. |
Antikörper mit korrigiertem CDR
|
AU2005219839B9
(en)
|
2004-03-01 |
2011-12-22 |
Immune Disease Institute, Inc |
Natural IgM antibodies and inhibitors thereof
|
WO2005088308A2
(en)
*
|
2004-03-12 |
2005-09-22 |
The Scripps Research Institute |
Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities
|
EP2293069A3
(de)
|
2004-03-24 |
2011-09-21 |
Tripath Imaging, Inc. |
Verfahren und Zusammensetzungen zum Nachweis von zervikalen Erkrankungen
|
WO2005097184A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
RU2386638C2
(ru)
|
2004-03-31 |
2010-04-20 |
Дженентек, Инк. |
Гуманизированные анти-тфр-бета-антитела
|
ES2338344T3
(es)
*
|
2004-04-07 |
2010-05-06 |
Rinat Neuroscience Corporation |
Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
TWI556829B
(zh)
|
2004-04-09 |
2016-11-11 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CA2955027A1
(en)
|
2004-04-15 |
2005-11-10 |
University Of Florida Research Foundation, Inc. |
Neural proteins as biomarkers for nervous system injury and other neural disorders
|
AU2005250333A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Genentech, Inc. |
Omi PDZ modulators
|
WO2005110015A2
(en)
|
2004-04-19 |
2005-11-24 |
Ohio University |
Cross-linkable glycoproteins and methods of making the same
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
EP1789453A2
(de)
*
|
2004-05-18 |
2007-05-30 |
Genentech, Inc. |
Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
|
EP1602928A1
(de)
*
|
2004-06-01 |
2005-12-07 |
Universiteit Maastricht |
Verfahren und Kit zur Bestimmung der Bindungsparameter von Bioaffinitätsbindungsreaktionen
|
CN102453763A
(zh)
|
2004-06-03 |
2012-05-16 |
阿什洛米克斯控股有限公司 |
诊断应激的药物和方法
|
CA2568644C
(en)
*
|
2004-06-03 |
2015-11-24 |
Phylogica Limited |
Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
|
US7604947B2
(en)
*
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
JP2008503217A
(ja)
*
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
EP2474317A1
(de)
*
|
2004-06-24 |
2012-07-11 |
Biogen Idec MA Inc. |
Behandlung von Zuständen einhergehend mit Demyelisation
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
CN101014365B
(zh)
|
2004-07-16 |
2011-04-13 |
辉瑞产品公司 |
使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
|
CN102641503A
(zh)
*
|
2004-07-20 |
2012-08-22 |
健泰科生物技术公司 |
血管生成素样4蛋白抑制剂,组合,以及其用途
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
BRPI0512396A
(pt)
*
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
US7342093B2
(en)
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
US7807165B2
(en)
*
|
2004-07-30 |
2010-10-05 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
US20070087400A1
(en)
*
|
2004-07-30 |
2007-04-19 |
Aldis Darzins |
Covalent tethering of functional groups to proteins and substrates therefor
|
US7425436B2
(en)
|
2004-07-30 |
2008-09-16 |
Promega Corporation |
Covalent tethering of functional groups to proteins and substrates therefor
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
SI2322556T1
(sl)
*
|
2004-09-03 |
2016-02-29 |
Genentech, Inc. |
Humanizirani antagonisti proti beta7 in njihove uporabe
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
WO2006047325A1
(en)
|
2004-10-21 |
2006-05-04 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
WO2006066088A2
(en)
*
|
2004-12-16 |
2006-06-22 |
Genentech, Inc. |
Methods for treating autoimmune disorders
|
BRPI0519430A2
(pt)
|
2004-12-22 |
2009-02-10 |
Ambrx Inc |
hormânio do crescimento humano modificado
|
ZA200704934B
(en)
|
2004-12-22 |
2010-09-29 |
Genentech Inc |
Methods for producing soluble multi-membrane-spanning proteins
|
WO2006073846A2
(en)
*
|
2004-12-22 |
2006-07-13 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
CN101087875B
(zh)
*
|
2004-12-22 |
2012-08-22 |
Ambrx公司 |
氨酰基-tRNA合成酶的组合物及其用途
|
MX2007007587A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
|
EP2311881A3
(de)
|
2005-01-05 |
2011-07-27 |
Biogen Idec MA Inc. |
Cripto-bindende Moleküle
|
EA018897B1
(ru)
|
2005-01-05 |
2013-11-29 |
Ф-Стар Биотехнологише Форшунгс- Унд Энтвиклунгсгез.М.Б.Х. |
Молекулы иммуноглобулина, содержащие модифицированные участки структурных петель, обладающие свойством связывания, и способ их получения
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
US7713695B2
(en)
|
2005-02-07 |
2010-05-11 |
Genenews, Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
EP2548575A1
(de)
|
2005-02-15 |
2013-01-23 |
Duke University |
Anti-CD19-Antikörper die ADCC vermitteln zur Verwendung in der Behandlung von Autoimmunkrankheiten
|
WO2006096565A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
EP2491926B1
(de)
|
2005-03-22 |
2018-05-09 |
President and Fellows of Harvard College |
Behandlung von Proteinabbaustörungen
|
EP2567976B1
(de)
|
2005-03-23 |
2017-07-19 |
Genmab A/S |
Antikörper gegen CD38 zur Behandling von multiplem Myelom
|
GB0506912D0
(en)
|
2005-04-05 |
2005-05-11 |
Celltech R&D Ltd |
Biological products
|
WO2006113665A2
(en)
|
2005-04-15 |
2006-10-26 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
EP1871418B1
(de)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
|
DOP2006000093A
(es)
|
2005-04-25 |
2007-01-31 |
Pfizer |
Anticuerpos contra miostatina
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
AR054260A1
(es)
*
|
2005-04-26 |
2007-06-13 |
Rinat Neuroscience Corp |
Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
MY148086A
(en)
*
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
EP2500037A3
(de)
|
2005-05-16 |
2012-10-24 |
Abbott Biotechnology Ltd |
Verwendung eines TNF-Hemmers zur Behandlung von erosiver Polyarthritis
|
WO2007001677A2
(en)
|
2005-05-17 |
2007-01-04 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism
|
CA2726759C
(en)
|
2005-05-25 |
2016-02-16 |
Curedm Group Holdings, Llc |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
KR20080023317A
(ko)
|
2005-05-27 |
2008-03-13 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Tweak 결합 항체
|
CA2609205A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
WO2006135886A2
(en)
*
|
2005-06-13 |
2006-12-21 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ES2402650T3
(es)
|
2005-06-17 |
2013-05-07 |
Janssen Alzheimer Immunotherapy |
Métodos de purificación de anticuerpos anti A beta
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
JP2009501006A
(ja)
|
2005-06-30 |
2009-01-15 |
セントカー・インコーポレーテツド |
抗il−23抗体、組成物、方法および用途
|
CN103145842A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
CN101501215A
(zh)
|
2005-07-07 |
2009-08-05 |
阿什洛米克斯控股有限公司 |
用于诊断内毒素血症的多核苷酸标记基因及它们的表达
|
BRPI0613387A2
(pt)
|
2005-07-08 |
2011-01-11 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
|
EP1904652A2
(de)
*
|
2005-07-08 |
2008-04-02 |
Brystol-Myers Squibb Company |
Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
|
CA2615615A1
(en)
|
2005-07-22 |
2007-02-01 |
Y's Therapeutics Co., Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
ATE470151T1
(de)
|
2005-08-02 |
2010-06-15 |
Xbiotech Inc |
Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
|
EP1920057A4
(de)
|
2005-08-03 |
2009-03-18 |
Grains Res & Dev Corp |
Polysaccharid-synthasen
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
CN101273140B
(zh)
|
2005-08-18 |
2013-01-16 |
Ambrx公司 |
tRNA组合物和其用途
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
MY169746A
(en)
|
2005-08-19 |
2019-05-14 |
Abbvie Inc |
Dual variable domain immunoglobulin and uses thereof
|
EP2500353A3
(de)
|
2005-08-19 |
2012-10-10 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
RS54393B1
(en)
|
2005-09-07 |
2016-04-28 |
Amgen Fremont Inc. |
HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
|
CA2620362A1
(en)
*
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A. |
Comb polymers
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
KR101176830B1
(ko)
|
2005-10-17 |
2012-08-27 |
주식회사 아이지세라피 |
신규한 파아지 디스플레이 방법
|
EP1945816B1
(de)
|
2005-10-21 |
2011-07-27 |
GeneNews Inc. |
Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
|
US8597646B2
(en)
|
2005-10-25 |
2013-12-03 |
The Johns Hopkins University |
Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
|
RS54215B1
(en)
|
2005-10-31 |
2015-12-31 |
Oncomed Pharmaceuticals, Inc. |
COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
|
AU2006308847C1
(en)
*
|
2005-10-31 |
2012-05-10 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
CA2626804A1
(en)
|
2005-11-01 |
2007-08-09 |
Abbott Biotechnology Ltd. |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
EP1957531B1
(de)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
|
CN101500592A
(zh)
|
2005-11-07 |
2009-08-05 |
斯克利普斯研究院 |
控制组织因子信号转导特异性的组合物和方法
|
CN104710503B
(zh)
*
|
2005-11-08 |
2023-04-25 |
Ambrx 公司 |
用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
US7807790B2
(en)
|
2005-11-14 |
2010-10-05 |
Metamol Theranostics, Llc |
Peptide sequence that promotes tumor invasion
|
AP2008004467A0
(en)
|
2005-11-14 |
2008-06-30 |
Rinat Neurosciene Corp |
Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
|
WO2007059312A2
(en)
*
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
EP1963369B1
(de)
|
2005-11-28 |
2013-05-15 |
Zymogenetics, Inc. |
Il-21-antagonisten
|
DK1954718T3
(en)
|
2005-11-30 |
2014-12-15 |
Abbvie Inc |
Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
|
EP1976877B2
(de)
|
2005-11-30 |
2016-10-05 |
AbbVie Inc. |
Monoklonale antikörper gegen das amyloid-beta-protein und anwendungen davon
|
RU2470941C2
(ru)
*
|
2005-12-02 |
2012-12-27 |
Дженентек, Инк. |
Связывающие полипептиды и их применения
|
EP3006466B1
(de)
|
2005-12-02 |
2018-08-01 |
Genentech, Inc. |
Zusammensetzungen und verfahren für die behandlung von krankheiten und störungen in zusammenhang mit der zytokinsignalisierung
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
EP2314626A1
(de)
|
2005-12-09 |
2011-04-27 |
UCB Pharma, S.A. |
Antikörpermoleküle mit menschlicher IL-6-Spezifizität
|
CA2882445A1
(en)
*
|
2005-12-14 |
2007-06-21 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
EP1973948B1
(de)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Verfahren und zusammensetzungen zum targeting von polyubiquitin
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
SI3219328T1
(sl)
|
2005-12-29 |
2020-10-30 |
Janssen Biotech, Inc. |
Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
|
AU2007248444B2
(en)
|
2006-01-05 |
2012-10-25 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
TW200804422A
(en)
|
2006-01-12 |
2008-01-16 |
Alexion Pharma Inc |
Antibodies to OX-2/CD200 and uses thereof
|
AU2007211085A1
(en)
|
2006-01-27 |
2007-08-09 |
Tripath Imaging, Inc. |
Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
WO2007090126A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Invitrogen Corporation |
Compositions and methods for detecting and quantifying toxic substances in disease states
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
JP5259423B2
(ja)
|
2006-02-01 |
2013-08-07 |
セファロン・オーストラリア・ピーティーワイ・リミテッド |
ドメイン抗体構築物
|
CN101400362B
(zh)
|
2006-02-14 |
2016-10-12 |
哈佛大学校长及研究员协会 |
双官能组蛋白去乙酰化酶抑制剂
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
EP1987178B1
(de)
*
|
2006-02-20 |
2015-03-25 |
Phylogica Limited |
Verfahren für den aufbau und die durchsuche von peptidstrukturbibliotheken
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
US20080019961A1
(en)
*
|
2006-02-21 |
2008-01-24 |
Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
WO2007100640A2
(en)
*
|
2006-02-21 |
2007-09-07 |
The Regents Of The University Of Michigan |
Growth hormone receptor antagonist cancer treatment
|
EP2010677A4
(de)
*
|
2006-02-24 |
2010-04-14 |
Investigen Inc |
Verfahren und zusammensetzungen zum nachweis von polynukleotiden
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2010569A4
(de)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
Für gastrin spezifische humane antikörper, materialien und methoden
|
RU2466740C2
(ru)
|
2006-04-05 |
2012-11-20 |
Эбботт Байотекнолоджи Лтд. |
Очистка антитела
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
WO2008063213A2
(en)
|
2006-04-10 |
2008-05-29 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
WO2007121147A2
(en)
|
2006-04-10 |
2007-10-25 |
Genentech, Inc. |
Disheveled pdz modulators
|
EP2708242A3
(de)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Morbus Bechterew
|
AU2007297565A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
CA2654540C
(en)
|
2006-05-03 |
2017-01-17 |
President And Fellows Of Harvard College |
Histone deacetylase and tubulin deacetylase inhibitors
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
EP2016101A2
(de)
*
|
2006-05-09 |
2009-01-21 |
Genentech, Inc. |
Bindung von polypeptiden mit optimierten gerüsten
|
WO2007134132A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
KR20140085544A
(ko)
|
2006-05-30 |
2014-07-07 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
CA2654000A1
(en)
|
2006-06-06 |
2008-05-22 |
Genentech, Inc. |
Anti-dll4 antibodies and methods using same
|
RU2461572C2
(ru)
*
|
2006-06-07 |
2012-09-20 |
Биоэллаенс К.В. |
Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения
|
EP2815764A1
(de)
|
2006-06-14 |
2014-12-24 |
Macrogenics, Inc. |
Verfahren zur Behandlung von Autoimmunerkrankungen anhand von monoklonalen Antikörpern mit reduzierter Toxizität
|
AU2007281876B2
(en)
|
2006-06-26 |
2013-09-05 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
DE102006030028A1
(de)
*
|
2006-06-29 |
2008-02-14 |
Forschungszentrum Jülich GmbH |
Verfahren zum Auffinden von spezifisch an einen Köder bindende Moleküle, sowie spezifisch an einen Köder bindende Moleküle und deren Verwendung
|
KR101396797B1
(ko)
|
2006-06-30 |
2014-05-26 |
애브비 바이오테크놀로지 리미티드 |
자동 주사 장치
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
EP2046951B1
(de)
|
2006-07-05 |
2011-10-26 |
Catalyst Biosciences, Inc. |
Protease-screening-verfahren und dadurch identifizierte proteasen
|
ZA200900545B
(en)
|
2006-07-18 |
2010-03-31 |
Sanofi Aventis |
Antagonist antibody against EPHA2 for the treatment of cancer
|
MX2009001291A
(es)
|
2006-08-04 |
2009-03-10 |
Astrazeneca Ab |
Anticuerpos para erbb2.
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
JP5209625B2
(ja)
|
2006-08-28 |
2013-06-12 |
協和発酵キリン株式会社 |
アンタゴニストのヒトlight特異的ヒトモノクローナル抗体
|
DK2089722T3
(en)
|
2006-09-07 |
2018-01-22 |
Otago Innovation Ltd |
BIOMARKET FOR EARLY DETECTION OF ACUTE HEART DISORDERS
|
SG10201508485UA
(en)
|
2006-09-08 |
2015-11-27 |
Abbvie Bahamas Ltd |
Interleukin - 13 binding proteins
|
EP2615108B1
(de)
*
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
|
KR20090052360A
(ko)
*
|
2006-09-08 |
2009-05-25 |
암브룩스, 인코포레이티드 |
척추동물 세포에서의 서프레서 tRNA 전사
|
CA2662753C
(en)
*
|
2006-09-08 |
2016-02-23 |
Ambrx, Inc. |
Hybrid suppressor trna for vertebrate cells
|
EP2845912A1
(de)
|
2006-09-12 |
2015-03-11 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Diagnose und Behandlung von Lungenkrebs mithilfe des KIT-Gens als genetischem Marker
|
EP2074138A4
(de)
*
|
2006-09-19 |
2009-12-30 |
Phylogica Ltd |
Neuroprotektive peptidinhibitoren der ap-1-signalvermittlung und anwendungen davon
|
JP5476122B2
(ja)
|
2006-09-26 |
2014-04-23 |
ゲンマブ エー/エス |
Cd38発現腫瘍の併用処置法
|
DK2066694T3
(en)
|
2006-09-29 |
2016-02-08 |
Oncomed Pharm Inc |
Compositions and Methods for Diagnosing and Treating Cancer
|
NZ576032A
(en)
|
2006-10-12 |
2012-03-30 |
Genentech Inc |
Antibodies to lymphotoxin-alpha
|
MX2009003542A
(es)
|
2006-10-12 |
2009-04-15 |
Wyeth Corp |
Metodos y composiciones con opalescencia reducida.
|
EP2064335A4
(de)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
US20080096193A1
(en)
*
|
2006-10-24 |
2008-04-24 |
Charles Robert Bupp |
Methods and compositions for detecting polynucleotides
|
DK2502938T3
(en)
|
2006-10-27 |
2015-04-20 |
Genentech Inc |
Antibodies and immunoconjugates and uses thereof
|
WO2008054821A2
(en)
|
2006-10-30 |
2008-05-08 |
Promega Corporation |
Mutant hydrolase proteins with enhanced kinetics and functional expression
|
EP2064315B1
(de)
|
2006-11-03 |
2015-05-13 |
Wyeth LLC |
Glycolysehemmstoffe in zellkulturen
|
CN101641106A
(zh)
|
2006-11-15 |
2010-02-03 |
功能遗传学股份有限公司 |
抗-tsg101抗体及其用于治疗病毒感染的用途
|
US8785400B2
(en)
*
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
US7488807B2
(en)
|
2006-11-22 |
2009-02-10 |
3M Innovative Properties Company |
Antibody with protein A selectivity
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008067547A2
(en)
*
|
2006-11-30 |
2008-06-05 |
Research Development Foundation |
Improved immunoglobulin libraries
|
DK2099823T4
(da)
|
2006-12-01 |
2022-05-09 |
Seagen Inc |
Målbindingsmiddelvarianter og anvendelser deraf
|
EA017529B1
(ru)
|
2006-12-05 |
2013-01-30 |
Декоуд Дженетикс Ехф. |
Генетические маркеры для предотвращения риска аритмии сердца
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
KR20140148491A
(ko)
|
2006-12-19 |
2014-12-31 |
제넨테크, 인크. |
조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 vegf-특이적 길항제
|
EP2094306A2
(de)
|
2006-12-20 |
2009-09-02 |
XOMA Technology Ltd. |
Behandlung von il-1-beta-bedingten erkrankungen
|
US20100129358A1
(en)
|
2006-12-22 |
2010-05-27 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US20090068110A1
(en)
*
|
2006-12-22 |
2009-03-12 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
NZ629273A
(en)
|
2006-12-27 |
2015-02-27 |
Harvard College |
Compositions and methods for the treatment of infections and tumors
|
WO2008082651A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Dual-specific il-1a/ il-1b antibodies
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
EA036660B1
(ru)
|
2007-01-09 |
2020-12-04 |
Байоджен Эмэй Инк. |
АНТИТЕЛО К Sp35 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ
|
RU2475265C2
(ru)
|
2007-01-16 |
2013-02-20 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
WO2008092002A2
(en)
*
|
2007-01-24 |
2008-07-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
EP2629094A1
(de)
|
2007-01-24 |
2013-08-21 |
Carnegie Mellon University |
Optische Biosensoren
|
US8865400B2
(en)
|
2007-02-07 |
2014-10-21 |
Decode Genetics Ehf. |
Genetic variants contributing to risk of prostate cancer
|
KR20090114443A
(ko)
|
2007-02-09 |
2009-11-03 |
제넨테크, 인크. |
항-Robo4 항체 및 그의 용도
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
WO2008101184A2
(en)
*
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
SG178811A1
(en)
|
2007-02-21 |
2012-03-29 |
Decode Genetics Ehf |
Genetic susceptibility variants associated with cardiovascular disease
|
AU2008218199B2
(en)
|
2007-02-22 |
2013-10-31 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
WO2008103702A2
(en)
*
|
2007-02-23 |
2008-08-28 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2447719B1
(de)
|
2007-02-26 |
2016-08-24 |
Oxford BioTherapeutics Ltd |
Proteine
|
EP2486928A1
(de)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Verfahren zur Behandlung von Amyloidosen
|
CN103214577B
(zh)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
WO2008114020A2
(en)
|
2007-03-22 |
2008-09-25 |
Heptares Therapeutics Limited |
Mutant g-protein coupled receptors and methods for selecting them
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
KR20160121601A
(ko)
|
2007-03-30 |
2016-10-19 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
US20110130544A1
(en)
|
2007-03-30 |
2011-06-02 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
CL2008000935A1
(es)
|
2007-04-02 |
2008-11-07 |
Amgen Fremont Inc |
Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
|
DE602007013110D1
(de)
*
|
2007-04-04 |
2011-04-21 |
Chimera Biotec Gmbh |
Verfahren zum nachweis eines analyten in einer biologischen matrix
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
JP5761782B2
(ja)
|
2007-04-13 |
2015-08-12 |
カタリスト・バイオサイエンシーズ・インコーポレイテッドCatalyst Biosciences, Inc. |
改変第vii因子ポリペプチド及びその使用
|
EP2076533B1
(de)
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modifizierte interferon-beta-polypeptide und ihre verwendungen
|
AU2008246442B2
(en)
|
2007-05-04 |
2014-07-03 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
KR20100017514A
(ko)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
항 icos 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
|
CA2986531C
(en)
|
2007-05-14 |
2020-02-25 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
CA2687556A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Genentech, Inc. |
Crystal structures of neuropilin fragments and neuropilin-antibody complexes
|
MX2009012722A
(es)
|
2007-05-25 |
2009-12-11 |
Decode Genetics Ehf |
Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
|
US7906149B2
(en)
*
|
2007-05-25 |
2011-03-15 |
Boval Company, L.P. |
Method for treating allergic dermatitis
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
CA2958672A1
(en)
|
2007-06-15 |
2008-12-18 |
Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts |
Treatment of tumors using specific anti-l1 antibody
|
EP2170932A4
(de)
*
|
2007-06-20 |
2012-10-10 |
Phylogica Ltd |
Zusammensetzungen und anwendungen davon bei der behandlung von akutem atemnotsyndrom (ards) und damit assoziierten klinischen erkrankungen
|
CN101821288A
(zh)
|
2007-06-21 |
2010-09-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
JP5602625B2
(ja)
|
2007-06-26 |
2014-10-08 |
エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング |
結合物質のディスプレイ
|
US8158758B2
(en)
|
2007-07-02 |
2012-04-17 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
BRPI0813514A2
(pt)
|
2007-07-16 |
2019-09-24 |
Genentech Inc |
anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
|
PT2474557E
(pt)
|
2007-07-16 |
2014-12-03 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
JP2010534664A
(ja)
|
2007-07-23 |
2010-11-11 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
Il−17拮抗薬を用いた線維症関連疾患治療の方法及び組成物
|
MX2010000979A
(es)
*
|
2007-07-25 |
2010-03-26 |
Alexion Pharma Inc |
Metodos y composiciones para tratar enfermedad autoinmune.
|
US20100273722A1
(en)
*
|
2007-08-06 |
2010-10-28 |
Yale University |
Modified miniature proteins
|
US9062097B2
(en)
|
2007-08-21 |
2015-06-23 |
Morpho Sys AG |
Methods for the formation of disulphide bonds
|
AU2008292913B2
(en)
*
|
2007-08-30 |
2014-06-05 |
Curedm Group Holdings, Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
BRPI0816785A2
(pt)
*
|
2007-09-14 |
2017-05-02 |
Adimab Inc |
bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
|
US8629246B2
(en)
|
2007-09-26 |
2014-01-14 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
NZ584330A
(en)
*
|
2007-10-04 |
2013-01-25 |
Bionomics Ltd |
Markers of endothelial cells and uses thereof
|
RU2530561C2
(ru)
|
2007-11-05 |
2014-10-10 |
Медиммун, Ллк |
Способы лечения склеродермии
|
SG185972A1
(en)
|
2007-11-07 |
2012-12-28 |
Genentech Inc |
Compositions and methods for treatment of microbial disorders
|
CA2705486C
(en)
|
2007-11-19 |
2019-04-02 |
Celera Corporation |
Lung cancer markers and uses thereof
|
US8946148B2
(en)
|
2007-11-20 |
2015-02-03 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
US9308257B2
(en)
*
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
AR069501A1
(es)
*
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
US8697360B2
(en)
|
2007-11-30 |
2014-04-15 |
Decode Genetics Ehf. |
Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
|
US8426153B2
(en)
|
2007-12-03 |
2013-04-23 |
Carnegie Mellon University |
Linked peptides fluorogenic biosensors
|
GB0724051D0
(en)
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
CN102216329A
(zh)
|
2007-12-17 |
2011-10-12 |
辉瑞有限公司 |
间质性膀胱炎的治疗
|
EP2245063B1
(de)
|
2007-12-18 |
2015-08-26 |
BioAlliance C.V. |
Antikörper, die ein kohlenhydrathaltiges, auf krebszellen exprimiertes epitop auf cd-43 und cea erkennen und verfahren zu deren verwendung
|
PL2391650T3
(pl)
|
2007-12-20 |
2015-03-31 |
Xoma Us Llc |
Sposoby leczenia dny
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
US8637026B2
(en)
|
2007-12-26 |
2014-01-28 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
PT2237803E
(pt)
|
2007-12-28 |
2015-10-16 |
Prothena Biosciences Ltd |
Tratamento e profilaxia da amiloidose
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
KR101597842B1
(ko)
|
2008-01-11 |
2016-02-25 |
가부시키가이샤 진 테크노 사이언스 |
인간화된 항-알파9 인테그린 항체 및 그의 용도
|
ES2613963T3
(es)
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
SI2247620T1
(sl)
|
2008-01-31 |
2016-09-30 |
Genentech, Inc. |
Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
|
NZ586947A
(en)
|
2008-02-08 |
2012-11-30 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
PL2250279T3
(pl)
|
2008-02-08 |
2016-11-30 |
|
Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
|
GB0802474D0
(en)
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
AU2009213689B2
(en)
|
2008-02-14 |
2014-11-20 |
Decode Genetics Ehf. |
Susceptibility variants for lung cancer
|
US8697374B2
(en)
|
2008-02-28 |
2014-04-15 |
3M Innovative Properties Company |
Antibodies to Clostridium difficile spores and uses thereof
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
WO2009109572A2
(en)
*
|
2008-03-03 |
2009-09-11 |
Ablynx Nv |
Monovalent phage display of single variable domains
|
DK2265288T3
(en)
|
2008-03-04 |
2016-06-06 |
Labrys Biologics Inc |
Methods for the treatment of inflammatory pain
|
BRPI0907135B8
(pt)
|
2008-03-04 |
2021-05-25 |
Labrys Biologics Inc |
uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8507209B2
(en)
|
2008-03-12 |
2013-08-13 |
Otago Innovation Limited |
Biomarkers
|
EP2265641B1
(de)
|
2008-03-12 |
2018-01-24 |
Otago Innovation Limited |
Biomarker
|
US9873957B2
(en)
*
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
KR20100126515A
(ko)
|
2008-03-18 |
2010-12-01 |
아보트 러보러터리즈 |
건선의 치료방법
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
EP2271770B1
(de)
*
|
2008-03-31 |
2018-08-22 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung und diagnose von asthma
|
NZ588905A
(en)
|
2008-04-01 |
2012-08-31 |
Decode Genetics Ehf |
Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease
|
BRPI0906309A2
(pt)
|
2008-04-02 |
2020-05-26 |
Macrogenics, Inc |
Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
|
CN102046655B
(zh)
|
2008-04-02 |
2016-09-14 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
ES2588194T3
(es)
|
2008-04-11 |
2016-10-31 |
Seattle Genetics, Inc. |
Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
JP5780951B2
(ja)
|
2008-04-24 |
2015-09-16 |
ダイアックス コーポレーション |
新規のhccdr1、cdr2、およびcdr3設計、ならびに新規のlccdr1、cdr2、およびcdr3設計を含む、遺伝子パッケージのライブラリ
|
US8614296B2
(en)
|
2008-04-24 |
2013-12-24 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
|
SG196839A1
(en)
|
2008-04-25 |
2014-02-13 |
Dyax Corp |
Antibodies against fcrn and use thereof
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2113255A1
(de)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Zytotoxisches Immunglobulin
|
ES2458541T3
(es)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
|
ES2605471T3
(es)
|
2008-05-06 |
2017-03-14 |
Genentech, Inc. |
Variantes de CRIg de afinidad madurada
|
KR101649168B1
(ko)
|
2008-05-09 |
2016-08-18 |
애브비 인코포레이티드 |
최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도
|
CA2723614C
(en)
*
|
2008-05-16 |
2015-07-14 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
EP2599793A1
(de)
|
2008-05-29 |
2013-06-05 |
Nuclea Biotechnologies, Inc. |
Anti-Phosphor-AKT-Antikörper
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
WO2009149189A2
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
EP2282770B1
(de)
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2010004591A2
(en)
|
2008-07-07 |
2010-01-14 |
Decode Genetics Ehf |
Genetic variants for breast cancer risk assessment
|
BRPI0915448A2
(pt)
|
2008-07-08 |
2015-11-10 |
Abbott Lab |
imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
|
CN102143760B
(zh)
|
2008-07-08 |
2015-06-17 |
Abbvie公司 |
前列腺素e2结合蛋白及其用途
|
PT2307459E
(pt)
|
2008-07-08 |
2015-03-11 |
Oncomed Pharm Inc |
Agentes de ligação a receptor notch1 e métodos da sua utilização
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
JP5986745B2
(ja)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカAcademia Sinica |
Ptfe様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
RU2515611C2
(ru)
|
2008-07-23 |
2014-05-20 |
Президент Энд Феллоуз Оф Гарвард Колледж |
Ингибиторы деацетилазы и их применение
|
US9182406B2
(en)
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
BRPI0917000A2
(pt)
|
2008-08-06 |
2016-02-16 |
Novo Nordisk Healthcare Ag |
proteínas conjugadas com eficácia in vivo prolongada
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
EA026110B1
(ru)
|
2008-08-14 |
2017-03-31 |
Сефалон Острэйлиа Пти Лтд. |
Антитела против il-12/il-23
|
CA3073384A1
(en)
|
2008-09-05 |
2010-03-11 |
President And Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
US20100081575A1
(en)
*
|
2008-09-22 |
2010-04-01 |
Robert Anthony Williamson |
Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
|
WO2010033229A2
(en)
*
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of molecules and displayed molecules and collections
|
WO2010039536A2
(en)
|
2008-09-23 |
2010-04-08 |
President And Fellows Of Harvard College |
Sirt4 and uses thereof
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
NZ601659A
(en)
*
|
2008-09-26 |
2014-02-28 |
Ambrx Inc |
Modified animal erythropoietin polypeptides and their uses
|
EA201170493A1
(ru)
|
2008-09-26 |
2011-10-31 |
Амбркс, Инк. |
Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
|
SG190568A1
(en)
|
2008-09-26 |
2013-06-28 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
WO2010036856A2
(en)
|
2008-09-26 |
2010-04-01 |
Wyeth Llc |
Compatible display vector systems
|
DK2340038T3
(en)
|
2008-10-10 |
2018-02-26 |
Childrens Medical Ct Corp |
BIOCHEMICALLY STABILIZED HIV-1-ENV TRIMER VACCINE
|
EP2349329A4
(de)
|
2008-10-14 |
2012-10-31 |
Dyax Corp |
Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose
|
EP2360172B1
(de)
|
2008-10-20 |
2017-10-18 |
Gwangju Institute of Science and Technology |
Bipodaler peptidbinder
|
TWI610936B
(zh)
|
2008-10-20 |
2018-01-11 |
艾伯維有限公司 |
使用蛋白質a親和性層析進行抗體之分離及純化
|
US20120251502A1
(en)
|
2008-10-24 |
2012-10-04 |
The Government of the US as Represented by the Secretary of the Dept. of health |
Human Ebola Virus Species and Compositions and Methods Thereof
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
CN102272154A
(zh)
|
2008-10-29 |
2011-12-07 |
惠氏有限责任公司 |
单域抗原结合性分子的纯化方法
|
EP2346904B1
(de)
|
2008-10-29 |
2017-04-12 |
China Synthetic Rubber Corporation |
Methoden und mittel zur diagnose und behandlung von hepatozellulärem karzinom
|
CA3149920A1
(en)
|
2008-10-31 |
2010-05-06 |
Janssen Biotech, Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
US9403904B2
(en)
|
2008-11-07 |
2016-08-02 |
Fabrus, Inc. |
Anti-DLL4 antibodies and uses thereof
|
CA3035432A1
(en)
|
2008-11-10 |
2010-05-14 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
AU2009314141B2
(en)
|
2008-11-11 |
2013-11-07 |
The Regents Of The University Of Michigan |
Anti-CXCR1 compositions and methods
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
ATE523603T1
(de)
*
|
2008-11-21 |
2011-09-15 |
Chimera Biotec Gmbh |
Konjugatkomplexe zum analytnachweis
|
PL2361085T5
(pl)
|
2008-11-22 |
2018-12-31 |
F.Hoffmann-La Roche Ag |
Zastosowanie przeciwciała anty-vegf w połączeniu z chemioterapią w leczeniu raka sutka
|
RU2011121042A
(ru)
|
2008-11-26 |
2013-01-10 |
Файв Прайм Терапеутикс, Инк. |
Композиции и способы регулирования экспрессии коллагена и актина гладких мышц посредством serpine2
|
CA2744449C
(en)
|
2008-11-28 |
2019-01-29 |
Emory University |
Methods for the treatment of infections and tumors
|
US20100233079A1
(en)
*
|
2008-12-04 |
2010-09-16 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
SG196798A1
(en)
|
2008-12-09 |
2014-02-13 |
Genentech Inc |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
SG172254A1
(en)
|
2008-12-19 |
2011-07-28 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
MX2011006875A
(es)
|
2008-12-23 |
2011-07-20 |
Genentech Inc |
Metodos y composiciones para uso en diagnostico de pacientes con cancer.
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
WO2010082134A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
BRPI1007345A2
(pt)
|
2009-01-20 |
2019-04-16 |
H. ZADEH Homayoun |
regeneração óssea de anticorpo mediado
|
JP2012515544A
(ja)
|
2009-01-21 |
2012-07-12 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Pta089タンパク質
|
MX2011007736A
(es)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
US20100310591A1
(en)
*
|
2009-01-28 |
2010-12-09 |
Robert Humphreys |
Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
MX2011007987A
(es)
|
2009-01-29 |
2011-08-17 |
Abbott Lab |
Proteinas de enlace il-1.
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
RU2562700C2
(ru)
|
2009-02-12 |
2015-09-10 |
Янссен Байотек, Инк. |
Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
JP5782385B2
(ja)
|
2009-02-17 |
2015-09-24 |
ユーシービー ファーマ ソシエテ アノニム |
ヒトox40に対する特異性を有する抗体分子
|
WO2010096388A2
(en)
|
2009-02-18 |
2010-08-26 |
Carnegie Mellon University |
Quenched dendrimeric dyes for bright detection
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
US20100227335A1
(en)
|
2009-03-05 |
2010-09-09 |
Becton, Dickinson And Company |
Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Il-17結合蛋白
|
CA2753713A1
(en)
|
2009-03-06 |
2010-09-10 |
Tripath Imaging, Inc |
Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
JP5995442B2
(ja)
|
2009-03-10 |
2016-09-21 |
株式会社ジーンテクノサイエンス |
ヒト化k33nモノクローナル抗体の作製、発現及び解析
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
MX345909B
(es)
|
2009-03-25 |
2017-02-22 |
Genentech Inc |
Anticuerpos anti-fgfr3 y métodos que los utilizan.
|
MX2011010012A
(es)
|
2009-03-25 |
2011-12-06 |
Genentech Inc |
NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
WO2010113185A1
(en)
|
2009-04-03 |
2010-10-07 |
Decode Genetics Ehf |
Genetic markers for risk management of atrial fibrillation and stroke
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
MA33276B1
(fr)
|
2009-04-20 |
2012-05-02 |
Oxford Biotherapeutics Ltd |
Anticorps spécifiques à la cadhérine-17
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
EP2799453B1
(de)
|
2009-04-29 |
2019-04-03 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Monoklonale ERG2-Antikörper und deren therapeutische Verwendung
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
BRPI1011195B1
(pt)
*
|
2009-05-20 |
2020-10-13 |
Novimmune S.A |
métodos para produzir uma coleção de ácidos nucleicos
|
US8680055B2
(en)
|
2009-06-03 |
2014-03-25 |
University Of Southern California |
Methods for decreasing steroidogenesis in prostate cancer cells
|
EP2261242A1
(de)
|
2009-06-10 |
2010-12-15 |
Universite Catholique De Louvain |
Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
|
EP3329932A1
(de)
|
2009-06-10 |
2018-06-06 |
New York University |
Immunologisches targeting von pathologischen tau-proteinen
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
EP2445520A4
(de)
|
2009-06-22 |
2013-03-06 |
Medimmune Llc |
Manipulierte fc-regionen für standortspezifische konjugation
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
EP2272979A1
(de)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
|
SG177583A1
(en)
|
2009-07-09 |
2012-02-28 |
Hoffmann La Roche |
In vivo tumor vasculature imaging
|
CA2767360A1
(en)
|
2009-07-10 |
2011-01-13 |
Decode Genetics Ehf. |
Genetic markers associated with risk of diabetes mellitus
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
US9259476B2
(en)
|
2009-07-31 |
2016-02-16 |
Wayne State University |
Monophosphorylated lipid A derivatives
|
AU2010278844A1
(en)
|
2009-07-31 |
2012-02-09 |
Genentech, Inc. |
Inhibition of tumor metastasis using Bv8- or G-CSF-antagonists
|
WO2011014771A1
(en)
|
2009-07-31 |
2011-02-03 |
Wayne State University |
Monophosphorylated lipid a derivatives
|
CN105963710A
(zh)
|
2009-08-06 |
2016-09-28 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
WO2011019393A2
(en)
|
2009-08-11 |
2011-02-17 |
President And Fellows Of Harvard College |
Class- and isoform-specific hdac inhibitors and uses thereof
|
EP3431588A1
(de)
|
2009-08-11 |
2019-01-23 |
F. Hoffmann-La Roche AG |
Herstellung von proteinen in glutamin-freien zellkulturmedien
|
CA2770737C
(en)
|
2009-08-13 |
2020-05-12 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
US20110047103A1
(en)
|
2009-08-15 |
2011-02-24 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
AU2010288194B2
(en)
|
2009-08-28 |
2013-08-29 |
Teva Pharmaceuticals International Gmbh |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
TWI465250B
(zh)
|
2009-08-29 |
2014-12-21 |
Abbvie Inc |
治療用之dll4結合蛋白質
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
JP2013503607A
(ja)
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2475682B1
(de)
|
2009-09-10 |
2018-01-31 |
UCB Biopharma SPRL |
Polyvalente antikörper
|
CA2773564A1
(en)
*
|
2009-09-14 |
2011-03-17 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
MX2012003138A
(es)
|
2009-09-14 |
2012-07-04 |
Abbott Lab Y Abbott Gmbh & Co Kg |
Metodos para tratar la psoriasis.
|
BR112012005670A2
(pt)
|
2009-09-17 |
2017-01-10 |
Hoffmann La Roche |
''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
EP2480573A1
(de)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs durch modulation von mex-3
|
EP3187877A1
(de)
|
2009-09-25 |
2017-07-05 |
XOMA Technology Ltd. |
Screening-verfahren
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
WO2011036555A1
(en)
|
2009-09-25 |
2011-03-31 |
University Of Oslo |
Multivalent phage display systems and methods
|
EP2483407A2
(de)
|
2009-09-30 |
2012-08-08 |
President and Fellows of Harvard College |
Verfahren zur autophagie-modulation durch modulation autophagie-verstärkender genprodukte
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
RU2012119756A
(ru)
|
2009-10-15 |
2013-11-20 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
PT2488204E
(pt)
|
2009-10-16 |
2016-06-09 |
Oncomed Pharm Inc |
Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos
|
CN102711828B
(zh)
|
2009-10-20 |
2015-06-17 |
Abbvie公司 |
使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
AU2010310585A1
(en)
|
2009-10-22 |
2012-05-03 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
WO2011051350A1
(en)
|
2009-10-27 |
2011-05-05 |
Ucb Pharma S.A. |
Function modifying nav 1.7 antibodies
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
EP2496605A1
(de)
|
2009-11-02 |
2012-09-12 |
Oxford Biotherapeutics Ltd. |
Ror1 als therapeutisches und diagnostisches ziel
|
US20120277144A1
(en)
|
2009-11-04 |
2012-11-01 |
Henricus Johannes Duckers |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
US8361744B2
(en)
|
2009-11-05 |
2013-01-29 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
CA2780024A1
(en)
|
2009-11-11 |
2011-05-19 |
Gentian As |
Immunoassay for assessing related analytes of different origin
|
WO2011060272A2
(en)
|
2009-11-13 |
2011-05-19 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
ES2562832T3
(es)
|
2009-12-08 |
2016-03-08 |
Abbvie Deutschland Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
|
CA2783740C
(en)
|
2009-12-09 |
2020-03-10 |
Institut National De La Sante Et De La Recherche Medicale |
Monoclonal antibodies that bind b7h6 and uses thereof
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
US8937159B2
(en)
*
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
WO2011087810A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
SG2014011340A
(en)
|
2009-12-21 |
2014-07-30 |
Genentech Inc |
Antibody formulation
|
MX349301B
(es)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Polipéptidos de somatotropina bovina modificados y sus usos.
|
PL2516465T3
(pl)
|
2009-12-23 |
2016-11-30 |
|
Przeciwciała anty-bv8 i ich zastosowania
|
TW201125583A
(en)
*
|
2009-12-23 |
2011-08-01 |
Bioalliance Cv |
Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
|
DK3459564T3
(da)
|
2010-01-06 |
2022-02-07 |
Takeda Pharmaceuticals Co |
Plasmakallikreinbindende proteiner
|
RU2012134369A
(ru)
|
2010-01-11 |
2014-02-20 |
Алексион Фармасьютикалз, Инк |
Биомаркеры иммуномодулирующих эффектов у людей, подвергнутых лечению антиметаллами против cd200
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
MX2012008085A
(es)
|
2010-01-13 |
2012-09-12 |
Oncomed Pharm Inc |
Agentes de union notch1 y metodos de uso de los mismos.
|
US9745589B2
(en)
|
2010-01-14 |
2017-08-29 |
Cornell University |
Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
|
WO2011091134A2
(en)
|
2010-01-22 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
PL2525834T3
(pl)
|
2010-01-22 |
2020-10-19 |
Novo Nordisk Health Care Ag |
Hormony wzrostu o przedłużonej skuteczności in-vivo
|
JP5980689B2
(ja)
|
2010-01-22 |
2016-08-31 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
WO2011097301A2
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
AU2011215900A1
(en)
|
2010-02-10 |
2012-07-26 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
US10393754B2
(en)
|
2010-02-17 |
2019-08-27 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating heart failure
|
EP2536748B1
(de)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin-antagonisten und ihre verwendung zur behandlung von krebs
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
SG183414A1
(en)
|
2010-02-23 |
2012-09-27 |
Genentech Inc |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
RU2740479C2
(ru)
|
2010-02-24 |
2021-01-14 |
Иммьюноджен, Инк. |
Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование
|
TWI552760B
(zh)
|
2010-02-24 |
2016-10-11 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
PE20130580A1
(es)
|
2010-03-02 |
2013-06-02 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
CN102844332B
(zh)
|
2010-03-11 |
2015-08-19 |
瑞纳神经科学公司 |
呈pH依赖性抗原结合的抗体
|
CA2792618C
(en)
|
2010-03-12 |
2018-09-25 |
Immunogen, Inc. |
Cd37-binding molecules and immunoconjugates thereof
|
EP2547359B1
(de)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Hemmer von interaktionen, die beta-integrin-g protein-alpha-untereinheit binden
|
US20130045871A1
(en)
*
|
2010-03-18 |
2013-02-21 |
Cornell University |
Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
|
EP2550529B1
(de)
|
2010-03-23 |
2021-11-17 |
Iogenetics, LLC. |
Bioinformatikverfahren zur bestimmung von peptidbindungen
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US10472426B2
(en)
|
2010-03-25 |
2019-11-12 |
Ucb Biopharma Sprl |
Disulfide stabilized DVD-Ig molecules
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
JP2013530929A
(ja)
|
2010-04-01 |
2013-08-01 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
frizzled結合剤およびその使用
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
EP2380909A1
(de)
|
2010-04-26 |
2011-10-26 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
An Brustkrebs beteiligtes Protein PTK-7
|
WO2011137395A1
(en)
|
2010-04-30 |
2011-11-03 |
Rother Russell P |
Anti-c5a antibodies and methods for using the antibodies
|
CA2797121C
(en)
|
2010-05-03 |
2020-07-14 |
University Of Rochester |
Anti-glucosaminidase passive immunization for staphylococcus aureus infections
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
AU2011252883B2
(en)
|
2010-05-14 |
2015-09-10 |
Abbvie Inc. |
IL-1 binding proteins
|
WO2011141823A2
(en)
|
2010-05-14 |
2011-11-17 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
EP2577309B1
(de)
|
2010-05-25 |
2016-11-23 |
Carnegie Mellon University |
Gezielte sonden für zellphysiologie
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
WO2011153477A2
(en)
|
2010-06-03 |
2011-12-08 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
MX336109B
(es)
|
2010-06-03 |
2016-01-08 |
Genentech Inc |
Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
|
WO2012047324A2
(en)
|
2010-06-10 |
2012-04-12 |
President And Fellows Of Harvard College |
Systems and methods for amplification and phage display
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
MX2012014838A
(es)
|
2010-06-16 |
2013-02-07 |
Abbvie Inc |
Comparacion de las muestras de proteina.
|
AR082017A1
(es)
|
2010-06-18 |
2012-11-07 |
Genentech Inc |
Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
CN106188284B
(zh)
|
2010-07-09 |
2020-05-08 |
扬森疫苗与预防公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
KR102159272B1
(ko)
|
2010-07-16 |
2020-09-24 |
아디맵 엘엘씨 |
항체 라이브러리
|
JP2013536175A
(ja)
|
2010-07-16 |
2013-09-19 |
アブリンクス エン.ヴェー. |
修飾された単一ドメイン抗原結合分子及びその使用
|
CN103140498B
(zh)
|
2010-07-19 |
2017-05-17 |
奥塔哥创新有限公司 |
信号生物标志物
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US20130143815A1
(en)
|
2010-07-22 |
2013-06-06 |
Novo Nordisk Health Care Ag |
Growth hormone conjugates
|
SG187592A1
(en)
|
2010-07-23 |
2013-03-28 |
Univ Boston |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012015758A2
(en)
|
2010-07-30 |
2012-02-02 |
Saint Louis University |
Methods of treating pain
|
US8862410B2
(en)
|
2010-08-02 |
2014-10-14 |
Population Diagnostics, Inc. |
Compositions and methods for discovery of causative mutations in genetic disorders
|
EP2601216B1
(de)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
EP3252072A3
(de)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne und verwendungen davon
|
CA2806855A1
(en)
|
2010-08-03 |
2012-02-09 |
F. Hoffmann - La Roche Ag |
Chronic lymphocytic leukemia (cll) biomarkers
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
KR101673653B1
(ko)
|
2010-08-13 |
2016-11-08 |
로슈 글리카트 아게 |
항-fap 항체 및 이의 사용 방법
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
RS65223B1
(sr)
|
2010-08-17 |
2024-03-29 |
Ambrx Inc |
Modifikovani polipeptidi relaksina i njihova primena
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
US9505829B2
(en)
|
2010-08-19 |
2016-11-29 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
CN103109190B
(zh)
|
2010-08-19 |
2015-07-22 |
霍夫曼-拉罗奇有限公司 |
用于测量结合治疗性单克隆抗体的抗体的测定法
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
WO2012027570A2
(en)
|
2010-08-26 |
2012-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
JP2013539468A
(ja)
|
2010-08-27 |
2013-10-24 |
ステム セントリックス, インコーポレイテッド |
Notumタンパク質モジュレーターおよび使用法
|
EP3264089A1
(de)
|
2010-08-31 |
2018-01-03 |
Genentech, Inc. |
Biomarker und behandlungsverfahren
|
AU2011295715B9
(en)
|
2010-09-03 |
2017-02-23 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
MX2013003182A
(es)
|
2010-09-20 |
2013-04-24 |
Abbvie Inc |
Purificacion de anticuerpos por cromatografia de lecho movil simulada.
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
EP2446898A1
(de)
|
2010-09-30 |
2012-05-02 |
Laboratorios Del. Dr. Esteve, S.A. |
Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
|
US9005907B2
(en)
|
2010-10-01 |
2015-04-14 |
St. Jude Children's Research Hospital |
Methods and compositions for typing molecular subgroups of medulloblastoma
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
WO2012052391A1
(en)
|
2010-10-19 |
2012-04-26 |
Glaxo Group Limited |
Polypeptide with jmjd3 catalytic activity
|
EA201390575A1
(ru)
|
2010-10-29 |
2014-01-30 |
Иммьюноджен, Инк. |
Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
|
JP5828901B2
(ja)
|
2010-10-29 |
2015-12-09 |
イミュノジェン, インコーポレイテッド |
新規egfr結合分子およびその免疫抱合体
|
EA201390669A1
(ru)
|
2010-11-10 |
2013-11-29 |
Дженентек, Инк. |
Способы и композиции для иммунотерапии заболеваний нервной системы
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
EP2640831A1
(de)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
KR20190112175A
(ko)
|
2010-12-01 |
2019-10-02 |
앨더바이오 홀딩스 엘엘씨 |
항―ngf 조성물 및 그의 용도
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
PE20171143A1
(es)
|
2010-12-08 |
2017-08-10 |
Stem Centrx Inc |
Nuevos moduladores y metodos para su uso
|
EP2652498B1
(de)
|
2010-12-16 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Diagnose und behandlungen im zusammenhang mit th2-hemmung
|
CA2819269A1
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
CN103517921B
(zh)
|
2010-12-21 |
2017-07-18 |
Abbvie 公司 |
IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
|
US9394537B2
(en)
|
2010-12-22 |
2016-07-19 |
President And Fellows Of Harvard College |
Continuous directed evolution
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
KR101941514B1
(ko)
|
2010-12-22 |
2019-01-23 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
개선된 반감기를 가지는 변형된 항체
|
EP2658971A1
(de)
|
2010-12-28 |
2013-11-06 |
XOMA Technology Ltd. |
Zelloberflächendisplay mit pdz-domänen
|
US9598499B2
(en)
|
2010-12-30 |
2017-03-21 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CN103282054A
(zh)
|
2011-01-03 |
2013-09-04 |
弗·哈夫曼-拉罗切有限公司 |
抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
US8580265B2
(en)
|
2011-01-14 |
2013-11-12 |
Ucb Pharma S.A. |
Antibody molecules which bind IL-17A and IL-17F
|
EP2667918B1
(de)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatische injektionsvorrichtungen mit übersrpitzten griffflächen
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
CA2826453A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
WO2012109238A2
(en)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Methods for increasing immune responses using agents that directly bind to and activate ire-1
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012119129A1
(en)
|
2011-03-02 |
2012-09-07 |
Berg Biosystems, Llc |
Interrogatory cell-based assays and uses thereof
|
CA2865487A1
(en)
|
2011-03-07 |
2012-09-13 |
Paula J. Bates |
Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
GB2503604B
(en)
|
2011-03-21 |
2020-04-22 |
Biodesy Llc |
Classification of kinase inhibitors using second harmonic optical techniques
|
WO2012128810A1
(en)
|
2011-03-23 |
2012-09-27 |
Abbott Laboratories |
Methods and systems for the analysis of protein samples
|
RS57895B1
(sr)
|
2011-03-29 |
2019-01-31 |
Roche Glycart Ag |
Fc varijante antitela
|
JP6130350B2
(ja)
|
2011-03-30 |
2017-05-17 |
アブリンクス エン.ヴェー. |
TNFαに対する単一ドメイン抗体で免疫障害を処置する方法
|
WO2012134813A1
(en)
|
2011-03-31 |
2012-10-04 |
St. Jude Children's Research Hospital |
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
|
JP2014516511A
(ja)
|
2011-04-07 |
2014-07-17 |
ジェネンテック, インコーポレイテッド |
抗fgfr4抗体及び使用方法
|
CA2832565A1
(en)
|
2011-04-08 |
2012-10-11 |
Biogen Idec Ma Inc. |
Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
WO2012142526A1
(en)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Use of tumor fas expression to determine response to anti-cancer therapy
|
ES2669310T3
(es)
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
JP6038121B2
(ja)
|
2011-04-21 |
2016-12-07 |
ガーバン インスティテュート オブ メディカル リサーチ |
修飾された可変ドメイン分子及びその製造及び使用の方法b
|
ES2567276T3
(es)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
|
JP2014518624A
(ja)
|
2011-05-12 |
2014-08-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ニューログラニン診断キットのためのアッセイ試薬
|
PT2710035T
(pt)
|
2011-05-16 |
2017-06-05 |
Hoffmann La Roche |
Agonistas do fgfr1 e métodos de utilização
|
KR102030531B1
(ko)
|
2011-05-21 |
2019-10-10 |
마크로제닉스, 인크. |
탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
KR102014554B1
(ko)
|
2011-06-02 |
2019-08-26 |
다이액스 코포레이션 |
Fc 수용체 결합 단백질
|
MY192843A
(en)
|
2011-06-03 |
2022-09-12 |
Xoma Technology Ltd |
Antibodies specific for tgf-beta
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
RS57024B1
(sr)
|
2011-06-10 |
2018-05-31 |
Medimmune Ltd |
Anti-pseudomonas psl vezujući molekuli i njihova upotreba
|
RS57397B8
(sr)
|
2011-06-10 |
2020-01-31 |
Univ Oregon Health & Science |
Cmv glikoproteini i rekombinantni vektori
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
UA114478C2
(uk)
|
2011-06-28 |
2017-06-26 |
Берлін-Хемі Аг |
Антитіло, яке специфічно зв'язується з bst1
|
PT2726094T
(pt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Alvo terapêutico e de diagnóstico
|
US20130004484A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
KR20140061403A
(ko)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
|
WO2013008185A1
(en)
|
2011-07-14 |
2013-01-17 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
RU2014101669A
(ru)
|
2011-07-15 |
2015-09-20 |
Онкомед Фармасьютикалс, Инк. |
Агенты, связывающие белки r-спондины (rspo), и способы их применения
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法
|
CA2845536A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
CN103781801B
(zh)
|
2011-08-23 |
2018-02-09 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
EP3564261A1
(de)
|
2011-08-23 |
2019-11-06 |
Foundation Medicine, Inc. |
Kif5b-re-fusionsmoleküle und verwendungen davon
|
JP2014534806A
(ja)
|
2011-08-23 |
2014-12-25 |
ロシュ グリクアート アーゲー |
抗mcsp抗体
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
US20140234903A1
(en)
|
2011-09-05 |
2014-08-21 |
Eth Zurich |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
EP2753356B1
(de)
|
2011-09-09 |
2021-12-22 |
Medimmune Limited |
Anti-siglec-15 antikörper und ihre verwendungen
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
US10093705B2
(en)
|
2011-09-13 |
2018-10-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
EP2771349B1
(de)
|
2011-09-16 |
2020-02-26 |
Iogenetics, LLC. |
Bioinformatikverfahren zur bestimmung von peptidbindungen
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
RS58201B1
(sr)
|
2011-09-23 |
2019-03-29 |
Oncomed Pharm Inc |
Vegf/dll4 vezujući agensi i njihova upotreba
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
AU2012318306A1
(en)
|
2011-10-06 |
2014-04-24 |
The Board Of Trustees Of The University Of Illinois |
Myosin binding protein- C for use in methods relating to diastolic heart failure
|
WO2013054200A2
(en)
|
2011-10-10 |
2013-04-18 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
US8623821B2
(en)
|
2011-10-14 |
2014-01-07 |
Genentech, Inc. |
Zymogen activators
|
AR088322A1
(es)
|
2011-10-14 |
2014-05-28 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
US9193766B2
(en)
|
2011-10-14 |
2015-11-24 |
Genentech, Inc. |
Peptide inhibitors of BACE1
|
CN103998027A
(zh)
|
2011-10-15 |
2014-08-20 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的scd1拮抗剂
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
RS20140203A1
(en)
|
2011-10-24 |
2014-10-31 |
Abbvie Inc. |
IMMUNOVELING PROTEINS AGAINST TNF
|
EP2771360A1
(de)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Gegen sclerostin gerchtet immunbinder
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773664A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
EP2785376B1
(de)
|
2011-11-02 |
2019-09-18 |
University Of Rochester |
Passive immunisierung gegen glucosaminidase für staphylococcus aureus-infektionen
|
JP6301258B2
(ja)
|
2011-11-03 |
2018-03-28 |
トライパス イメージング インコーポレイテッド |
免疫染色試料を調製するための方法および構成物
|
EP2773779B1
(de)
|
2011-11-04 |
2020-10-14 |
Population Bio, Inc. |
Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
|
CN104136042B
(zh)
|
2011-11-07 |
2017-08-18 |
米迪缪尼有限公司 |
使用抗假单胞菌Psl和PcrV结合分子的联合治疗
|
US20140294732A1
(en)
|
2011-11-08 |
2014-10-02 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Early diagnostic of neurodegenerative diseases
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
BR112014011304B1
(pt)
|
2011-11-11 |
2022-03-03 |
UCB Biopharma SRL |
Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
|
CN104053672A
(zh)
|
2011-11-11 |
2014-09-17 |
瑞纳神经科学公司 |
Trop-2特异性抗体及其用途
|
JP2014533954A
(ja)
|
2011-11-21 |
2014-12-18 |
イミュノジェン, インコーポレイテッド |
Egfr抗体細胞傷害性薬物複合体による、egfr療法に耐性である腫瘍の治療方法
|
JP2014533700A
(ja)
|
2011-11-21 |
2014-12-15 |
ジェネンテック, インコーポレイテッド |
抗c−MET抗体の精製
|
RU2620068C2
(ru)
|
2011-11-23 |
2017-05-22 |
МЕДИММЬЮН, ЭлЭлСи |
Связывающие молекулы, специфичные по отношению к her3, и их применения
|
RU2014124530A
(ru)
|
2011-11-23 |
2015-12-27 |
Идженика, Инк. |
Антитела к cd98 и способы их применения
|
US20140017174A1
(en)
|
2011-11-30 |
2014-01-16 |
Raja Atreya |
Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
EP3800200A1
(de)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
US9636398B2
(en)
|
2011-12-14 |
2017-05-02 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
JP6320300B2
(ja)
|
2011-12-19 |
2018-05-09 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
座瘡を治療するための方法
|
CN113896787A
(zh)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
KR102184059B1
(ko)
|
2011-12-22 |
2020-11-30 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
|
CN104011080B
(zh)
|
2011-12-22 |
2017-10-20 |
弗·哈夫曼-拉罗切有限公司 |
用于真核细胞的全长抗体展示系统及其用途
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
JP2015508994A
(ja)
|
2011-12-30 |
2015-03-26 |
アッヴィ・インコーポレイテッド |
Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
CA2860579A1
(en)
|
2012-01-10 |
2013-07-18 |
Biogen Idec Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
EP2804630B1
(de)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von fgf19-modulatoren
|
KR20140116490A
(ko)
|
2012-01-18 |
2014-10-02 |
제넨테크, 인크. |
항-lrp5 항체 및 사용 방법
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
LT2807192T
(lt)
|
2012-01-27 |
2018-07-25 |
AbbVie Deutschland GmbH & Co. KG |
Kompozicijos ir būdai, skirti ligų, susijusių su neuritų degeneracija, diagnostikai ir gydymui
|
WO2013120018A1
(en)
|
2012-02-09 |
2013-08-15 |
Population Diagnostics, Inc. |
Methods and compositions for screening and treating developmental disorders
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
WO2013120929A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
LT2814842T
(lt)
|
2012-02-15 |
2018-11-12 |
Novo Nordisk A/S |
Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
|
HUE036955T2
(hu)
|
2012-02-15 |
2018-08-28 |
Novo Nordisk As |
Antitestek, amelyek a trigger receptort kötik és blokkolják, amely Myeloid-sejteken-1 (TREM-1) van expresszálva
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
PT2817338T
(pt)
|
2012-02-24 |
2017-11-13 |
Abbvie Stemcentrx Llc |
Moduladores de dll3 e métodos de utilização
|
LT2825558T
(lt)
|
2012-03-13 |
2019-08-12 |
F. Hoffmann-La Roche Ag |
Derinių terapija, skirta kiaušidžių vėžiui gydyti
|
KR20140142293A
(ko)
|
2012-03-16 |
2014-12-11 |
제넨테크, 인크. |
조작된 입체형태적으로-안정화된 단백질
|
JP2015511598A
(ja)
|
2012-03-16 |
2015-04-20 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Pak1阻害剤を用いて黒色腫を治療する方法
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
DK2828282T3
(en)
|
2012-03-20 |
2018-03-05 |
Otago Innovation Ltd |
Biomarkers
|
WO2013139956A1
(en)
|
2012-03-22 |
2013-09-26 |
Thrombogenics Nv |
Antibodies abrogating cell binding to lactadherin
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
EP2831119A1
(de)
|
2012-03-28 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Idiotypische antikörper gegen hcmv und verwendungen davon
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
SG10201608234UA
(en)
|
2012-04-02 |
2016-11-29 |
Berg Llc |
Interrogatory cell-based assays and uses thereof
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
SG10201913376XA
(en)
|
2012-04-20 |
2020-02-27 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
NZ724395A
(en)
|
2012-04-24 |
2018-03-23 |
Thrombogenics Nv |
Anti-pdgf-c antibodies
|
CN104583776B
(zh)
|
2012-04-25 |
2016-09-07 |
比奥德赛公司 |
用于检测蛋白质的变构调节剂的方法
|
EP2844300B1
(de)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17-antikörper und immunkonjugate
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
CA2873623C
(en)
|
2012-05-14 |
2021-11-09 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
MX362497B
(es)
|
2012-05-15 |
2019-01-21 |
Eisai Inc |
Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
|
US20140010820A1
(en)
|
2012-05-21 |
2014-01-09 |
Abbvie, Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
KR101843614B1
(ko)
|
2012-05-23 |
2018-03-29 |
제넨테크, 인크. |
치료제의 선택 방법
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
ES2742379T3
(es)
|
2012-05-31 |
2020-02-14 |
Hoffmann La Roche |
Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
|
EP2859018B1
(de)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Anti-ngf-antikörper für hunde und verfahren dafür
|
AU2013271515A1
(en)
|
2012-06-06 |
2015-01-15 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the Hippo pathway and uses thereof
|
JP2015530867A
(ja)
|
2012-06-15 |
2015-10-29 |
ジェネンテック, インコーポレイテッド |
抗pcsk9抗体、製剤、投薬、及び使用方法
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
WO2014001557A1
(en)
|
2012-06-28 |
2014-01-03 |
Ucb Pharma S.A. |
A method for identifying compounds of therapeutic interest
|
EP2866831A1
(de)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
KR20150023938A
(ko)
|
2012-07-04 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
항-테오필린 항체 및 이의 사용 방법
|
EP2870242A1
(de)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
PL2870247T3
(pl)
|
2012-07-05 |
2019-10-31 |
Hoffmann La Roche |
Układ ekspresji i wydzielania
|
EP2869818A1
(de)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
|
SG11201500096YA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies
|
MA37840B1
(fr)
|
2012-07-09 |
2020-05-29 |
Genentech Inc |
Immunoconjugués comprenant des anticorps anti-cd79b
|
MX2015000357A
(es)
|
2012-07-09 |
2015-05-12 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd22.
|
AU2013288931A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
CN104428315B
(zh)
|
2012-07-13 |
2017-09-29 |
罗氏格黎卡特股份公司 |
双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US9297806B2
(en)
|
2012-08-01 |
2016-03-29 |
The Johns Hopkins University |
5-hydroxymethylcytosine in human cancer
|
US10457733B2
(en)
|
2012-08-03 |
2019-10-29 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
JP6464085B2
(ja)
|
2012-08-07 |
2019-02-06 |
ジェネンテック, インコーポレイテッド |
神経膠芽腫の治療のための併用療法
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
SG11201500938XA
(en)
|
2012-08-31 |
2015-04-29 |
Immunogen Inc |
Diagnostic assays and kits for detection of folate receptor 1
|
US9737493B2
(en)
|
2012-09-07 |
2017-08-22 |
University Of Louisville Research Foundation, Inc. |
Compositions and methods for modulating DNMT1 inhibitor activity
|
US9976180B2
(en)
|
2012-09-14 |
2018-05-22 |
Population Bio, Inc. |
Methods for detecting a genetic variation in subjects with parkinsonism
|
US10233495B2
(en)
|
2012-09-27 |
2019-03-19 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
CA2879768A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
CN109364250A
(zh)
|
2012-10-09 |
2019-02-22 |
比奥根Ma公司 |
联合治疗及用于治疗脱髓鞘病症的用途
|
CA3201072A1
(en)
|
2012-10-12 |
2014-04-17 |
The Brigham And Women's Hospital, Inc. |
Enhancement of the immune response
|
EP2911691B1
(de)
|
2012-10-23 |
2018-10-10 |
OncoMed Pharmaceuticals, Inc. |
Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
|
CA2889638A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
EP2914625A2
(de)
|
2012-11-01 |
2015-09-09 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler anti-vegf/dll4-domäne und verwendungen davon
|
US20150284472A1
(en)
|
2012-11-05 |
2015-10-08 |
Genzyme Corporation |
Compositions and methods for treating proteinopathies
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
PE20150956A1
(es)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
|
JP6480338B2
(ja)
|
2012-11-08 |
2019-03-06 |
セセン バイオ, インコーポレイテッド |
Il−6アンタゴニストおよびその使用
|
WO2014074942A1
(en)
|
2012-11-08 |
2014-05-15 |
Illumina, Inc. |
Risk variants of alzheimer's disease
|
CN104968367B
(zh)
|
2012-11-13 |
2018-04-13 |
弗·哈夫曼-拉罗切有限公司 |
抗血凝素抗体和使用方法
|
US10407503B2
(en)
|
2012-11-30 |
2019-09-10 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-Met
|
EA034757B1
(ru)
|
2012-12-10 |
2020-03-17 |
Байоджен Ма Инк. |
Антитела против антигена 2 дендритных клеток крови и их применение
|
TWI716339B
(zh)
|
2012-12-21 |
2021-01-21 |
荷蘭商台醫(有限合夥)公司 |
親水性自消耗連接子及彼等之共軛物
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
CA2896091C
(en)
|
2012-12-21 |
2018-06-19 |
Amplimmune, Inc. |
Anti-h7cr antibodies
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
AU2013202668B2
(en)
|
2012-12-24 |
2014-12-18 |
Adelaide Research & Innovation Pty Ltd |
Inhibition of cancer growth and metastasis
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
EP2945652B1
(de)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2948178A4
(de)
|
2013-01-25 |
2016-07-20 |
Thymon Llc |
Zusammensetzungen zur selektiven reduktion von zirkulierendem bioaktivem löslichem tnf und verfahren zur behandlung einer tnf-vermittelten erkrankung
|
EP2950885B1
(de)
|
2013-02-04 |
2018-11-21 |
Oncomed Pharmaceuticals, Inc. |
Verfahren und überwachung einer behandlung mit einem wnt-pfad-hemmer
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
US9968687B2
(en)
|
2013-02-22 |
2018-05-15 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibody drug conjugates
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
BR112015020054A2
(pt)
|
2013-02-25 |
2017-08-29 |
Genentech Inc |
Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
|
WO2014131715A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
US20160017017A1
(en)
*
|
2013-03-11 |
2016-01-21 |
Novo Nordisk Healthcare Ag |
Growth Hormone Compounds
|
CN105229035A
(zh)
*
|
2013-03-11 |
2016-01-06 |
诺和诺德保健股份有限公司 |
生长激素化合物
|
RU2019120404A
(ru)
|
2013-03-13 |
2019-08-06 |
Дженентек, Инк. |
Составы антител
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
RU2707092C2
(ru)
|
2013-03-13 |
2019-11-22 |
Дженентек, Инк. |
Составы со сниженным окислением
|
EP2968467B1
(de)
|
2013-03-13 |
2020-06-03 |
F.Hoffmann-La Roche Ag |
Formulierungen mit reduzierter oxydation
|
MX2015012825A
(es)
|
2013-03-14 |
2016-06-10 |
Abbott Lab |
Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
AU2014240431A1
(en)
|
2013-03-14 |
2015-08-27 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
SG11201507037XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Anti-b7-h4 antibodies and immunoconjugates
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
EP2968565A2
(de)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
|
EP2836515A1
(de)
|
2013-03-14 |
2015-02-18 |
AbbVie Inc. |
Zusammensetzungen aus schwach sauren spezies und verfahren zur herstellung und verwendung davon
|
BR112015023212A2
(pt)
|
2013-03-14 |
2017-11-21 |
Gill Parkash |
tratamento do câncer utilizando anticorpos que se ligam à grp78 da superfície celular
|
EP3712252A1
(de)
|
2013-03-15 |
2020-09-23 |
F. Hoffmann-La Roche AG |
Zellkulturzusammensetzungen mit antioxidantien und verfahren zur polypeptidherstellung
|
TW201522374A
(zh)
|
2013-03-15 |
2015-06-16 |
Genentech Inc |
抗crth2抗體及使用方法
|
TWI745671B
(zh)
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
AU2014240012A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Inc. |
Antibody drug conjugate (ADC) purification
|
KR20230070054A
(ko)
|
2013-03-15 |
2023-05-19 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
ES2727134T3
(es)
|
2013-03-15 |
2019-10-14 |
Abbvie Deutschland |
Formulaciones de conjugado de fármaco y anticuerpo anti-EGFR
|
EA201591806A1
(ru)
|
2013-03-15 |
2016-01-29 |
Байоджен Ма Инк. |
Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
|
US9441035B2
(en)
|
2013-03-15 |
2016-09-13 |
Genentech, Inc. |
Cell culture media and methods of antibody production
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
EA038918B1
(ru)
|
2013-03-15 |
2021-11-09 |
Зинджения, Инк. |
Пептид, связывающий рецептор эпидермального фактора роста, мультиспецифические комплексы, содержащие пептид и антитела, и их применение
|
US10160797B2
(en)
|
2013-03-15 |
2018-12-25 |
Sanofi Pasteur Biologics, Llc |
Antibodies against Clostridium difficile toxins and methods of using the same
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
JP2016520528A
(ja)
|
2013-03-15 |
2016-07-14 |
ジェネンテック, インコーポレイテッド |
癌の治療及び抗癌剤耐性の防止方法
|
WO2014145016A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
ES2841123T3
(es)
|
2013-04-05 |
2021-07-07 |
Formulacion Del Compuesto De La Hormona De Crecimiento |
Formulación del compuesto de la hormona de crecimiento
|
CA2944989A1
(en)
|
2013-04-08 |
2014-10-16 |
Cytodyn Inc. |
Felinized antibodies and methods of treating retroviral infections in felines
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
SG11201508911PA
(en)
|
2013-04-29 |
2015-11-27 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
WO2014177461A1
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
EP2992331A4
(de)
|
2013-04-30 |
2017-03-29 |
Université de Montréal |
Neuartige biomarker für akute myeloische leukämie
|
CA2911514A1
(en)
|
2013-05-06 |
2014-11-13 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
WO2014189973A2
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
JP6682426B2
(ja)
|
2013-05-24 |
2020-04-15 |
メディミューン,エルエルシー |
抗b7−h5抗体およびその使用
|
JP6824735B2
(ja)
|
2013-06-06 |
2021-02-03 |
ピエール、ファーブル、メディカマン |
抗C10orf54抗体およびその使用方法
|
EP3004877A4
(de)
|
2013-06-06 |
2017-04-19 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
EP3632467B1
(de)
|
2013-06-07 |
2023-09-27 |
Duke University |
Inhibitoren des komplementfaktors h
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
US9873740B2
(en)
|
2013-07-16 |
2018-01-23 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CA2919477A1
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
BR112016002008B1
(pt)
|
2013-08-02 |
2021-06-22 |
Pfizer Inc. |
Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
|
EP3030902B1
(de)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
Neues screening-verfahren zur behandlung von friedreich-ataxie
|
EP3036320B2
(de)
|
2013-08-19 |
2024-04-03 |
Biogen MA Inc. |
Steuerung der proteinglykosylierung durch kulturmediumsupplementation und zellkulturprozessparametern
|
CA3090644C
(en)
|
2013-08-26 |
2023-02-07 |
Biontech Research And Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewisa
|
JP2016531915A
(ja)
|
2013-08-28 |
2016-10-13 |
ステムセントリックス, インコーポレイテッド |
部位特異的抗体コンジュゲーション方法および組成物
|
US9993566B2
(en)
|
2013-08-28 |
2018-06-12 |
Abbvie Stemcentrx Llc |
SEZ6 modulators and methods of use
|
MX371496B
(es)
|
2013-08-30 |
2020-01-31 |
Immunogen Inc |
Anticuerpos y ensayos para la detección del receptor 1 de folato.
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
EP2848937A1
(de)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
|
EP3041484B1
(de)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
|
WO2015042108A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
WO2015048331A1
(en)
|
2013-09-25 |
2015-04-02 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
EP3048899B1
(de)
|
2013-09-25 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Verfahren zur virusinaktivierung auf einer säule
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
EP3626742A1
(de)
|
2013-09-27 |
2020-03-25 |
F. Hoffmann-La Roche AG |
Anti-pdl1-antikörper-formulierungen
|
US10414818B2
(en)
|
2013-09-27 |
2019-09-17 |
Roche Diagnostics Operations, Inc. |
Thermus thermophilus SlyD FKBP domain specific antibodies
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
PT3055332T
(pt)
|
2013-10-08 |
2019-12-09 |
Immunogen Inc |
Regimes de dosagem de imunoconjugados anti-folr1
|
CN105814078A
(zh)
|
2013-10-11 |
2016-07-27 |
豪夫迈·罗氏有限公司 |
Nsp4抑制剂及其使用方法
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
MX2016004802A
(es)
|
2013-10-18 |
2016-07-18 |
Genentech Inc |
Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
|
RU2016119425A
(ru)
|
2013-10-23 |
2017-11-28 |
Дженентек, Инк. |
Способы диагностики и лечения эозинофильных заболеваний
|
CN111443069A
(zh)
|
2013-10-28 |
2020-07-24 |
多茨技术公司 |
过敏原检测
|
EP3777980B1
(de)
|
2013-10-29 |
2023-12-06 |
President and Fellows of Harvard College |
Nuclear factor erythroid 2-like 2 (nrf2) zur verwendung in der behandlung der altersbedingten makuladegeneration
|
EP3066121A1
(de)
|
2013-11-07 |
2016-09-14 |
AbbVie Inc. |
Isolierung und reinigung von dvd-igs
|
FI3511422T3
(fi)
|
2013-11-12 |
2023-01-31 |
|
Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten
|
CN105940115B
(zh)
|
2013-11-15 |
2021-07-06 |
巴斯德研究所 |
恶性疟原虫青蒿素耐药性的分子标记物
|
CN111499742A
(zh)
|
2013-11-21 |
2020-08-07 |
豪夫迈·罗氏有限公司 |
抗-α-突触核蛋白抗体及使用方法
|
KR102362803B1
(ko)
|
2013-11-25 |
2022-02-14 |
페임웨이브 리미티드 |
암 치료를 위한 항-ceacam1 및 항-pd 항체를 포함하는 조성물
|
US20160297875A1
(en)
|
2013-12-07 |
2016-10-13 |
Case Western Reserve University |
Compositions and methods of treating thrombosis
|
CN106030310B
(zh)
|
2013-12-13 |
2019-01-04 |
通用医疗公司 |
可溶性高分子量(hmw)tau种类及其应用
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
ES2754209T3
(es)
|
2013-12-13 |
2020-04-16 |
Stora Enso Oyj |
Cartón multicapa
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
CN105934253A
(zh)
|
2013-12-17 |
2016-09-07 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
|
PL3083689T3
(pl)
|
2013-12-17 |
2020-10-19 |
Genentech, Inc. |
Przeciwciała anty-CD3 i sposoby ich zastosowania
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
JP2017500017A
(ja)
|
2013-12-20 |
2017-01-05 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
EP2960252A1
(de)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase zur Behandlung von Immunosuppression
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
WO2015175340A1
(en)
|
2014-05-13 |
2015-11-19 |
Bavarian Nordic, Inc. |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
|
KR102278429B1
(ko)
|
2014-01-03 |
2021-07-16 |
에프. 호프만-라 로슈 아게 |
공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
EP3092251B1
(de)
|
2014-01-06 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Monovalente shuttle-module für blut-hirn-schranke
|
CN105899534B
(zh)
|
2014-01-15 |
2020-01-07 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015134121A2
(en)
|
2014-01-20 |
2015-09-11 |
President And Fellows Of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JP6837840B2
(ja)
|
2014-01-24 |
2021-03-10 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
結合タンパク質及びその使用方法
|
SG11201605903SA
(en)
|
2014-01-24 |
2016-08-30 |
Genentech Inc |
Methods of using anti-steap1 antibodies and immunoconjugates
|
US11648335B2
(en)
|
2014-01-31 |
2023-05-16 |
Wake Forest University Health Sciences |
Organ/tissue decellularization, framework maintenance and recellularization
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
MY179105A
(en)
|
2014-02-08 |
2020-10-28 |
Genentech Inc |
Methods of treating alzheimer's disease
|
ES2873248T3
(es)
|
2014-02-08 |
2021-11-03 |
Hoffmann La Roche |
Métodos para tratar la enfermedad de Alzheimer
|
WO2015122995A1
(en)
|
2014-02-11 |
2015-08-20 |
Visterra, Inc. |
Antibody moleules to dengue virus and uses thereof
|
RS57608B1
(sr)
|
2014-02-12 |
2018-11-30 |
Hoffmann La Roche |
Anti-jagged1 antitela i načini primene
|
CN106550593A
(zh)
|
2014-02-21 |
2017-03-29 |
艾伯维施特姆森特克斯有限责任公司 |
用于黑素瘤的抗‑dll3抗体和药物缀合物
|
KR20160124165A
(ko)
|
2014-02-21 |
2016-10-26 |
제넨테크, 인크. |
항-il-13/il-17 이중특이적 항체 및 그의 용도
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
LT3116909T
(lt)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
Antikūno molekulės prieš lag-3 ir jų panaudojimas
|
HRP20211748T1
(hr)
|
2014-03-14 |
2022-02-18 |
F. Hoffmann - La Roche Ag |
Postupci i sastavi za sekreciju heterolognih polipeptida
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
MX2016012188A
(es)
|
2014-03-21 |
2017-04-27 |
Teva Pharmaceuticals Int Gmbh |
Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
WO2015148515A1
(en)
|
2014-03-24 |
2015-10-01 |
Biogen Ma Inc. |
Methods for overcoming glutamine deprivation during mammalian cell culture
|
EP3129767B1
(de)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reaktive markierungsverbindungen und ihre verwendungen
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
WO2015150446A1
(en)
|
2014-04-02 |
2015-10-08 |
F. Hoffmann-La Roche Ag |
Method for detecting multispecific antibody light chain mispairing
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
CA3208721A1
(en)
|
2014-04-08 |
2015-10-15 |
Boston Pharmaceuticals Inc. |
Binding molecules specific for il-21 and uses thereof
|
CA2943299A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Bispecific her2 antibodies
|
MA52909A
(fr)
|
2014-04-18 |
2021-04-21 |
Acceleron Pharma Inc |
Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
EA037613B1
(ru)
|
2014-04-27 |
2021-04-21 |
Фэймуэйв Лтд. |
Гуманизированные антитела против ceacam1
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
US9753036B2
(en)
|
2014-04-29 |
2017-09-05 |
Edp Biotech Corporation |
Methods and compositions for screening and detecting biomarkers
|
CA2947148C
(en)
|
2014-04-30 |
2022-02-08 |
Pfizer Inc. |
Anti-ptk7 antibody-drug conjugates
|
MA51519A
(fr)
|
2014-05-05 |
2020-11-11 |
Regeneron Pharma |
Animaux c5 et c3 humanisés
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
EP3149037A4
(de)
|
2014-05-27 |
2018-01-10 |
Academia Sinica |
Anti-her2-glykoantikörper und verwendungen davon
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
KR20170005142A
(ko)
|
2014-05-27 |
2017-01-11 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
MA40041B1
(fr)
|
2014-05-28 |
2021-03-31 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-gitr et leurs procédés d'utilisation
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
MY191346A
(en)
|
2014-06-03 |
2022-06-17 |
Xbiotech Inc |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
US9856324B2
(en)
|
2014-06-04 |
2018-01-02 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
MX2016016233A
(es)
|
2014-06-11 |
2017-03-31 |
Genentech Inc |
Anticuerpos anti-lgr5 y sus usos.
|
BR122023023170A2
(pt)
|
2014-06-13 |
2024-02-20 |
Acceleron Pharma Inc. |
Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
|
EP3154579A1
(de)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
Neue behandlung gegen das influenzavirus
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
AU2015276821A1
(en)
|
2014-06-20 |
2017-01-12 |
Abgenomics International Inc. |
Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
AU2015286604B2
(en)
|
2014-07-10 |
2019-08-15 |
Hd Immune Gmbh |
Substances and methods for the use in prevention and/or treatment in Huntington's disease
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
EP3169801A1
(de)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostische verfahren und zusammensetzungen zur behandlung von glioblastomen
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
RU2733735C2
(ru)
|
2014-07-15 |
2020-10-06 |
Дженентек, Инк. |
Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов mek
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
KR20240029114A
(ko)
|
2014-07-17 |
2024-03-05 |
노보 노르디스크 에이/에스 |
점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
|
ES2805475T3
(es)
|
2014-07-21 |
2021-02-12 |
Novartis Ag |
Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33
|
CN113846062A
(zh)
|
2014-07-25 |
2021-12-28 |
赛拉福柯蒂斯公司 |
用于嵌合抗原受体分子的调控表达的慢病毒载体
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
EP3193928A1
(de)
|
2014-08-06 |
2017-07-26 |
Rinat Neuroscience Corp. |
Verfahren zur senkung von ldl-cholesterin
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
EP3712171A1
(de)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Behandlung von krebs mit einem chimären cd123-antigenrezeptor
|
GB2558326B
(en)
|
2014-09-05 |
2021-01-20 |
Population Bio Inc |
Methods and compositions for inhibiting and treating neurological conditions
|
EP3188746A4
(de)
|
2014-09-05 |
2018-05-02 |
The Johns Hopkins University |
Capn9/capns2-aktivität als ziel für eine therapeutische strategie zur behandlung von myofibroblastendifferenzierung und assoziierten erkrankungen
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
SG10201809668TA
(en)
|
2014-09-12 |
2018-11-29 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
EP3659621A1
(de)
|
2014-09-13 |
2020-06-03 |
Novartis AG |
Kombinationstherapien gegen krebs
|
MX2017003121A
(es)
|
2014-09-15 |
2017-08-02 |
Genentech Inc |
Formulaciones de anticuerpos.
|
BR112017005202A2
(pt)
|
2014-09-16 |
2017-12-12 |
Symphogen As |
anticorpos anti-met e composições
|
RU2727663C2
(ru)
|
2014-09-17 |
2020-07-22 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
|
WO2016044697A1
(en)
|
2014-09-19 |
2016-03-24 |
The Johns Hopkins University |
Biomarkers of cognitive dysfunction
|
EP3197492A1
(de)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Behandlung mit anti-pcsk9- antikörpern
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
KR102554634B1
(ko)
|
2014-09-30 |
2023-07-11 |
도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 |
L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171)
|
TWI707870B
(zh)
|
2014-10-01 |
2020-10-21 |
英商梅迪繆思有限公司 |
針對替格瑞洛的抗體及使用方法
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
PE20171067A1
(es)
|
2014-10-14 |
2017-07-24 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US11124822B2
(en)
|
2014-10-17 |
2021-09-21 |
Carnegie Mellon University |
Enhanced biomolecule detection assays based on tyramide signal amplification and gammaPNA probes
|
WO2016077052A2
(en)
|
2014-10-22 |
2016-05-19 |
President And Fellows Of Harvard College |
Evolution of proteases
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
CA2965502A1
(en)
|
2014-10-24 |
2016-04-28 |
Bristol-Myers Squibb Company |
Modified fgf-21 polypeptides and uses thereof
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
JP6827415B2
(ja)
|
2014-10-31 |
2021-02-10 |
メレオ バイオファーマ 5 インコーポレイテッド |
疾患の処置のための併用療法
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
KR20170086540A
(ko)
|
2014-11-03 |
2017-07-26 |
제넨테크, 인크. |
T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
|
WO2016073791A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
JP6770966B2
(ja)
|
2014-11-05 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
SG10202008810QA
(en)
|
2014-11-05 |
2020-10-29 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
MX2017005148A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
EP3215530B9
(de)
|
2014-11-07 |
2020-09-09 |
Sesen Bio, Inc. |
Verbesserte il-6-antikörper
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
MY191423A
(en)
|
2014-11-10 |
2022-06-27 |
Medimmune Ltd |
Binding molecules specific for cd73 and uses thereof
|
US10093730B2
(en)
|
2014-11-10 |
2018-10-09 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
EP3552488A1
(de)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Tiermodell für nephropathie und mittel zur behandlung davon
|
EP3218407A1
(de)
|
2014-11-11 |
2017-09-20 |
Medimmune Limited |
Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
PL3218005T3
(pl)
|
2014-11-12 |
2023-05-02 |
Seagen Inc. |
Związki oddziałujące z glikanami i sposoby ich zastosowania
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
CN106999583A
(zh)
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
WO2016081440A1
(en)
|
2014-11-17 |
2016-05-26 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
MX2017006610A
(es)
|
2014-11-20 |
2017-09-29 |
Hoffmann La Roche |
Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
|
US11033637B2
(en)
|
2014-11-21 |
2021-06-15 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
SI3227336T1
(sl)
|
2014-12-05 |
2019-10-30 |
Hoffmann La Roche |
Protitelesa proti CD79b in postopki uporabe
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
AU2015360903B2
(en)
|
2014-12-08 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
|
JP2018502840A
(ja)
|
2014-12-10 |
2018-02-01 |
ジェネンテック, インコーポレイテッド |
血液脳関門受容体抗体及び使用方法
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PL3800202T3
(pl)
|
2014-12-11 |
2023-06-12 |
Pierre Fabre Medicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
TW201809008A
(zh)
|
2014-12-19 |
2018-03-16 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
JP7211703B2
(ja)
|
2014-12-22 |
2023-01-24 |
ザ ロックフェラー ユニバーシティー |
抗mertkアゴニスト抗体及びその使用
|
WO2016106286A1
(en)
|
2014-12-23 |
2016-06-30 |
Biodesy, Inc. |
Attachment of proteins to interfaces for use in nonlinear optical detection
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
CA2973317A1
(en)
|
2015-01-09 |
2016-07-14 |
Adalta Pty Ltd |
Cxcr4 binding molecules
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
WO2016118191A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
US10308719B2
(en)
|
2015-01-26 |
2019-06-04 |
The University Of Chicago |
IL13Rα2 binding agents and use thereof in cancer treatment
|
WO2016123593A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
EP3253793A4
(de)
|
2015-02-02 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Leichtkettige anti-surrogate-antikörper
|
EP3253875B1
(de)
|
2015-02-04 |
2020-01-08 |
H. Hoffnabb-La Roche Ag |
Tau-antisense-oligomere und verwendungen davon
|
EP3954993A1
(de)
|
2015-02-04 |
2022-02-16 |
Bristol-Myers Squibb Company |
Verfahren zur auswahl therapeutischer moleküle
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
SI3265123T1
(sl)
|
2015-03-03 |
2023-02-28 |
Kymab Limited |
Protitelesa, uporabe in postopki
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
EP3735982A1
(de)
|
2015-03-10 |
2020-11-11 |
The University of Massachusetts |
Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
|
KR20170127011A
(ko)
|
2015-03-16 |
2017-11-20 |
제넨테크, 인크. |
Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
PL3271389T3
(pl)
|
2015-03-20 |
2020-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizujące przeciwciała wiążące się z gp120 i ich stosowanie
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
PL3273992T3
(pl)
|
2015-03-23 |
2020-11-16 |
Jounce Therapeutics, Inc. |
Przeciwciała przeciwko icos
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
JP2018518152A
(ja)
|
2015-03-27 |
2018-07-12 |
ユニバーシティ オブ サザン カリフォルニア |
充実性腫瘍を処置するためのlhrに指向されたcar t細胞治療
|
AU2016243026B2
(en)
|
2015-04-03 |
2022-03-31 |
Eureka Therapeutics, Inc. |
Constructs targeting AFP peptide/MHC complexes and uses thereof
|
ES2820768T3
(es)
|
2015-04-03 |
2021-04-22 |
Xoma Technology Ltd |
Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
|
KR20180026370A
(ko)
|
2015-04-06 |
2018-03-12 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
비-골수제거적 컨디셔닝을 위한 조성물 및 방법
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
WO2016164503A1
(en)
|
2015-04-06 |
2016-10-13 |
Acceleron Pharma Inc. |
Alk7:actriib heteromultimers and uses thereof
|
EP3991748A3
(de)
|
2015-04-07 |
2022-08-24 |
Alector LLC |
Anti-sortilin-antikörper und verfahren zur verwendung davon
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
US10294304B2
(en)
|
2015-04-13 |
2019-05-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen
|
MY196625A
(en)
|
2015-04-13 |
2023-04-23 |
Pfizer |
Therapeutic Antibodies and Their Uses
|
US11299729B2
(en)
|
2015-04-17 |
2022-04-12 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
DK3283508T3
(en)
|
2015-04-17 |
2021-05-31 |
Alpine Immune Sciences Inc |
Immunomodulatory Proteins with Tunable Affinities
|
WO2016170022A1
(en)
|
2015-04-21 |
2016-10-27 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting znf555
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
JP7044553B2
(ja)
|
2015-04-24 |
2022-03-30 |
ジェネンテック, インコーポレイテッド |
結合ポリペプチドを含む細菌を特定する方法
|
AU2016256486B2
(en)
|
2015-04-29 |
2021-09-23 |
University Of South Australia |
Compositions and methods for administering antibodies
|
EP3288981A1
(de)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Maskierte anti-cd3-antikörper und verfahren zur verwendung
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
MA42059A
(fr)
|
2015-05-06 |
2018-03-14 |
Janssen Biotech Inc |
Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
|
CN115109158A
(zh)
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
EP3736287A1
(de)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmunantikörper zur verwendung in der hemmung des krebszellenwachstums
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
WO2016183326A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CA3025145A1
(en)
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
CN107660152B
(zh)
|
2015-05-27 |
2021-11-05 |
Ucb生物制药私人有限公司 |
用于治疗神经系统疾病的方法
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
MX2017015046A
(es)
|
2015-05-29 |
2018-05-17 |
Agenus Inc |
Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
WO2016196298A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Therapeutic and diagnolstic methods for cancer
|
AU2016270640B2
(en)
|
2015-05-29 |
2022-03-10 |
Abbvie Inc. |
Anti-CD40 antibodies and uses thereof
|
ES2784603T3
(es)
|
2015-06-02 |
2020-09-29 |
Novo Nordisk As |
Insulinas con extensiones recombinantes polares
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP7010473B2
(ja)
|
2015-06-04 |
2022-02-10 |
ユニバーシティ オブ サザン カリフォルニア |
Lym-1およびlym-2標的化car細胞免疫療法
|
EP3303386A1
(de)
|
2015-06-05 |
2018-04-11 |
Genentech, Inc. |
Anti-tau-antikörper und verfahren zur verwendung
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
EP3307771A2
(de)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33-antikörper und verfahren zur verwendung davon
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
EP4299073A3
(de)
|
2015-06-16 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Humanisierte und affinitätgereifte antikörper gegen fcrh5 und verfahren zur verwendung
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体及び使用方法
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
WO2016205531A2
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
US20180188257A1
(en)
|
2015-06-19 |
2018-07-05 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
WO2016207717A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
EP3313885A1
(de)
|
2015-06-29 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Typ-ii-cd20-antikörper zur verwendung in der organtransplantation
|
KR20180021177A
(ko)
|
2015-06-29 |
2018-02-28 |
이뮤노젠 아이엔씨 |
항-cd123 항체 및 이들의 접합체와 유도체
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
US10392674B2
(en)
|
2015-07-22 |
2019-08-27 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
WO2017015559A2
(en)
|
2015-07-23 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of bt toxins
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
EP3331550B1
(de)
|
2015-08-04 |
2022-11-02 |
Acceleron Pharma Inc. |
Zusammensetzung zur behandlung von myeloproliferativen erkrankungen
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CN108136006A
(zh)
|
2015-08-06 |
2018-06-08 |
佐马美国有限公司 |
针对胰岛素受体的抗体片段和其治疗低血糖的用途
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
JP6914919B2
(ja)
|
2015-08-28 |
2021-08-04 |
ジェネンテック, インコーポレイテッド |
抗ヒプシン抗体及びその使用
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
EP3344806A4
(de)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
Glycanarrays und verfahren zur verwendung
|
CN113896789A
(zh)
|
2015-09-15 |
2022-01-07 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
|
CN108601828B
(zh)
|
2015-09-17 |
2023-04-28 |
伊缪诺金公司 |
包含抗folr1免疫缀合物的治疗组合
|
KR20230079500A
(ko)
|
2015-09-18 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8에 결합하는 항체 및 그의 사용
|
PE20181363A1
(es)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
Variantes optimizadas de anticuerpos anti-vegf
|
CN109071644B
(zh)
|
2015-09-23 |
2023-09-19 |
昂考梅德药品有限公司 |
治疗癌症的方法和组合物
|
CA2999037A1
(en)
|
2015-09-23 |
2017-03-30 |
Cytoimmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
JP2018529719A
(ja)
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
|
MA43348A
(fr)
|
2015-10-01 |
2018-08-08 |
Novo Nordisk As |
Conjugués de protéines
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Antibodies against pd1 and methods of their use
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
US11161912B2
(en)
|
2015-10-13 |
2021-11-02 |
Technion Research & Development Foundation Limited |
Heparanase-neutralizing monoclonal antibodies
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10968277B2
(en)
|
2015-10-22 |
2021-04-06 |
Jounce Therapeutics, Inc. |
Gene signatures for determining ICOS expression
|
EP3842450A1
(de)
|
2015-10-23 |
2021-06-30 |
Eureka Therapeutics, Inc. |
Chimäre antikörper/t-zellrezeptorkonstrukte und verwendungen davon
|
SG11201802887PA
(en)
|
2015-10-27 |
2018-05-30 |
Ucb Biopharma Sprl |
Methods of treatment using anti-il-17a/f antibodies
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
US20210106661A1
(en)
|
2015-10-29 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
GB201519303D0
(en)
|
2015-11-02 |
2015-12-16 |
Imp Innovations Ltd |
Phagemid vector
|
US11273151B2
(en)
|
2015-11-04 |
2022-03-15 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
EP3371217A1
(de)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Screening-verfahren für multispezifische antikörper
|
TWI726936B
(zh)
|
2015-11-10 |
2021-05-11 |
美商麥迪紐有限責任公司 |
對asct2具專一性之結合分子及其用途
|
WO2017083515A2
(en)
|
2015-11-10 |
2017-05-18 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
IL302822A
(en)
|
2015-11-12 |
2023-07-01 |
Seagen Inc |
Compounds interacting with glycans and methods of use
|
US10550170B2
(en)
|
2015-11-23 |
2020-02-04 |
Acceleron Pharma Inc. |
Methods for treating vascular eye disorders with actrii antagonists
|
EP4285923A3
(de)
|
2015-11-25 |
2024-03-06 |
Visterra, Inc. |
Antikörpermoleküle gegen april und verwendungen davon
|
EP3383908A1
(de)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
|
CA3006769A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
WO2017097889A1
(en)
|
2015-12-10 |
2017-06-15 |
Katholieke Universiteit Leuven |
Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
|
KR20180094977A
(ko)
|
2015-12-17 |
2018-08-24 |
노파르티스 아게 |
c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
SG11201610782YA
(en)
|
2015-12-18 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
JP2019502753A
(ja)
|
2015-12-23 |
2019-01-31 |
ムーンショット ファーマ エルエルシー |
ナンセンス変異依存mRNA分解機構の抑制による免疫応答の誘導法
|
AU2016381694A1
(en)
|
2015-12-30 |
2018-07-05 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
CN108472379B
(zh)
|
2015-12-30 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
JP2019509714A
(ja)
|
2016-01-05 |
2019-04-11 |
ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. |
Pcsk9抗体、その抗原結合フラグメント及び医薬用途
|
TWI753875B
(zh)
|
2016-01-08 |
2022-02-01 |
美商美國全心醫藥生技股份有限公司 |
四價抗psgl-1抗體及其用途
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
JP2019504064A
(ja)
|
2016-01-08 |
2019-02-14 |
スカラー ロック インコーポレイテッドScholar Rock,Inc. |
抗プロ/潜在型ミオスタチン抗体およびその使用方法
|
CN114113625A
(zh)
|
2016-01-20 |
2022-03-01 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
TW201936640A
(zh)
|
2016-01-21 |
2019-09-16 |
美商輝瑞股份有限公司 |
對表皮生長因子受體變異體iii具特異性之抗體類及彼等之用途
|
TWI755547B
(zh)
|
2016-01-21 |
2022-02-21 |
美商輝瑞股份有限公司 |
靶向表皮生長因子受體變異體iii之嵌合型抗原受體
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
GB201602413D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Method
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
CA3015913A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
US10336784B2
(en)
|
2016-03-08 |
2019-07-02 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
CA3015277A1
(en)
|
2016-03-10 |
2017-09-14 |
Acceleron Pharma Inc. |
Activin type 2 receptor binding proteins and uses thereof
|
BR112018067951A2
(pt)
|
2016-03-10 |
2019-02-05 |
Viela Bio Inc |
moléculas que se ligam a ilt7 e métodos de uso destas
|
US11643459B2
(en)
|
2016-03-11 |
2023-05-09 |
Scholar Rock, Inc. |
TGFβ1-binding immunoglobulins and use thereof
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
US11767362B1
(en)
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
EP3430055B1
(de)
|
2016-03-17 |
2020-10-28 |
Oslo Universitetssykehus HF |
Gegen tumorassoziierte makrophagen gerichtete fusionsproteine zur behandlung von krebs
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
JP7155009B2
(ja)
|
2016-03-25 |
2022-10-18 |
ビステラ, インコーポレイテッド |
デングウイルスに対する抗体分子の製剤
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
BR112018070097A2
(pt)
|
2016-03-29 |
2019-02-12 |
Obi Pharma, Inc. |
anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CA3019164A1
(en)
|
2016-03-29 |
2017-10-05 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
CN116333140A
(zh)
|
2016-04-08 |
2023-06-27 |
埃缇健康公司D/B/A泽尔拜尔 |
网蛋白-1结合抗体及其用途
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
WO2017181098A2
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
CN109379889A
(zh)
|
2016-04-22 |
2019-02-22 |
台湾浩鼎生技股份有限公司 |
通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
|
EP3448881B1
(de)
|
2016-04-26 |
2023-06-07 |
Icahn School of Medicine at Mount Sinai |
Behandlung von hippo-pfad-mutanten tumoren und verfahren zur identifizierung von probanden als kandidaten für die behandlung
|
CN109071635B
(zh)
|
2016-05-02 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Contorsbody-单链靶标结合物
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
RU2022108606A
(ru)
|
2016-05-16 |
2022-04-11 |
Такеда Фармасьютикал Компани Лимитед |
Антитела к фактору ix padua
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
EP3465221B1
(de)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
|
BR112018074463A2
(pt)
|
2016-05-27 |
2019-03-06 |
Agenus Inc. |
anticorpos anti-tim-3 e métodos de uso dos mesmos.
|
RU2745748C2
(ru)
|
2016-06-02 |
2021-03-31 |
Эббви Инк. |
Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
|
WO2018220099A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
CA3025995C
(en)
|
2016-06-06 |
2023-08-08 |
F. Hoffmann-La Roche Ag |
Fusion proteins for ophthalmology with increased eye retention
|
EP3464280B1
(de)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
EP3481835A4
(de)
|
2016-07-05 |
2020-02-26 |
Blade Therapeutics, Inc. |
Calpain-modulatoren und therapeutische verwendungen davon
|
KR20190039937A
(ko)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
AU2017297404A1
(en)
|
2016-07-13 |
2019-01-24 |
Biogen Ma Inc. |
Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
EP3496739B1
(de)
|
2016-07-15 |
2021-04-28 |
Acceleron Pharma Inc. |
Zusammensetzungen enthaltend actriia-polypeptide zur verwendung bei der behandlung von pulmonaler hypertonie
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
KR20190052669A
(ko)
|
2016-07-15 |
2019-05-16 |
포세이다 테라퓨틱스, 인크. |
키메라 항원 수용체 및 사용 방법
|
US20190328784A1
(en)
|
2016-07-15 |
2019-10-31 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors (cars) specific for muc1 and methods for their use
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
CN110072545A
(zh)
|
2016-07-27 |
2019-07-30 |
台湾浩鼎生技股份有限公司 |
免疫原性/治疗性聚糖组合物及其用途
|
KR20190040972A
(ko)
|
2016-07-27 |
2019-04-19 |
악셀레론 파마 인코포레이티드 |
골섬유증 치료 방법 및 조성물
|
US11643456B2
(en)
|
2016-07-29 |
2023-05-09 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
KR102591955B1
(ko)
|
2016-07-29 |
2023-10-19 |
추가이 세이야쿠 가부시키가이샤 |
증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
|
WO2018026748A1
(en)
|
2016-08-01 |
2018-02-08 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
|
US11858980B2
(en)
|
2016-08-02 |
2024-01-02 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
CA3032146A1
(en)
|
2016-08-03 |
2018-02-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
KR20190077306A
(ko)
|
2016-08-05 |
2019-07-03 |
메디뮨 엘엘씨 |
항-o2 항체 및 이의 용도
|
WO2018025982A1
(ja)
|
2016-08-05 |
2018-02-08 |
中外製薬株式会社 |
Il-8関連疾患の治療用又は予防用組成物
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP3515944A4
(de)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
Verfahren zur behandlung von immunerkrankungen unter verwendung von pd-1 bindenden proteinen
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
WO2018057955A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
JP2019529463A
(ja)
|
2016-09-23 |
2019-10-17 |
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー |
群発頭痛の治療方法
|
RS64550B1
(sr)
|
2016-09-23 |
2023-09-29 |
Hoffmann La Roche |
Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
|
JP6937368B2
(ja)
|
2016-09-23 |
2021-09-22 |
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー |
難治性片頭痛の治療方法
|
CA3038679A1
(en)
|
2016-09-28 |
2018-04-05 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
JP2020500207A
(ja)
|
2016-09-28 |
2020-01-09 |
ブレード・セラピューティクス・インコーポレイテッド |
カルパインモジュレーター及びそれらの治療上の使用
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
MX2019003703A
(es)
|
2016-09-30 |
2020-08-13 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
|
WO2018067474A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing gfap status in patient samples
|
WO2018065501A1
(en)
|
2016-10-05 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Methods for preparing antibody drug conjugates
|
CN110198743B
(zh)
|
2016-10-05 |
2023-07-18 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
EP3523331A1
(de)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimäre antigenrezeptoren zur behandlung von krebs
|
IL265800B2
(en)
|
2016-10-11 |
2023-10-01 |
Agenus Inc |
Anti-LAG-3 antibodies and methods of using them
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
WO2018075408A1
(en)
|
2016-10-17 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
|
KR20190064636A
(ko)
|
2016-10-19 |
2019-06-10 |
메디뮨 엘엘씨 |
항-o1 항체 및 이의 용도
|
EP3532091A2
(de)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic-antikörper und verfahren zur verwendung
|
US11249082B2
(en)
|
2016-10-29 |
2022-02-15 |
University Of Miami |
Zika virus assay systems
|
MA46708B1
(fr)
|
2016-11-02 |
2021-10-29 |
Jounce Therapeutics Inc |
Anticorps anti-pd1 et leurs utilisations
|
AU2017355402A1
(en)
|
2016-11-02 |
2019-05-30 |
Health Research, Inc. |
Combination treatment with antibody-drug conjugates and PARP inhibitors
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
US11208474B2
(en)
|
2016-11-16 |
2021-12-28 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-IL23 specific antibody
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
AU2017361549B2
(en)
|
2016-11-21 |
2023-12-21 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
MA46893A
(fr)
|
2016-11-23 |
2019-10-02 |
Bioverativ Therapeutics Inc |
Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
|
JP7080234B2
(ja)
|
2016-11-23 |
2022-06-03 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
WO2018102594A1
(en)
|
2016-12-01 |
2018-06-07 |
Alexion Pharmaceuticals, Inc. |
Methods of treating solid tumors with anti-cd200 antibodies
|
CR20230163A
(es)
|
2016-12-07 |
2023-07-06 |
Genentech Inc |
ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
|
KR102603681B1
(ko)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
항체 및 이의 사용방법
|
LT3551660T
(lt)
|
2016-12-07 |
2023-12-27 |
Agenus Inc. |
Antikūnai prieš ctla-4 ir jų naudojimo būdai
|
KR20240035636A
(ko)
|
2016-12-07 |
2024-03-15 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
CA3043158A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
CN110088292A
(zh)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的方法
|
JP6850351B2
(ja)
|
2016-12-21 |
2021-03-31 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗体のインビトロ糖鎖工学
|
RU2019123063A
(ru)
|
2016-12-23 |
2021-01-26 |
Вистерра, Инк. |
Связывающие полипептиды и способы их получения
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
CA3049005A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive tgf.beta.1 inhibitors and use thereof
|
HUE061656T2
(hu)
|
2017-01-06 |
2023-07-28 |
Scholar Rock Inc |
Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
WO2018130661A1
(en)
|
2017-01-13 |
2018-07-19 |
Academia Sinica |
Reloadable hydrogel system for treating brain conditions
|
TWI659750B
(zh)
|
2017-01-13 |
2019-05-21 |
中央研究院 |
用以治療心肌梗塞之可重複裝載之改良水膠系統
|
AU2018211064A1
(en)
|
2017-01-18 |
2019-09-05 |
Genentech, Inc. |
Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
|
CN110431150A
(zh)
|
2017-01-18 |
2019-11-08 |
威特拉公司 |
抗体分子-药物偶联物及其用途
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
BR112019016143A2
(pt)
|
2017-02-06 |
2020-04-07 |
Australian Meat & Live Stock |
composições imunoestimulantes e usos das mesmas
|
CA3052578A1
(en)
|
2017-02-07 |
2018-08-16 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
TW201837051A
(zh)
|
2017-02-08 |
2018-10-16 |
美商必治妥美雅史谷比公司 |
包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
|
CN110494453B
(zh)
|
2017-02-10 |
2023-05-26 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US10765762B2
(en)
|
2017-02-27 |
2020-09-08 |
Regeneron Pharmaceuticals, Inc. |
Humanized model of kidney and liver disorders
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
EP3589650A1
(de)
|
2017-03-02 |
2020-01-08 |
Novartis AG |
Manipulierte heterodimere proteine
|
WO2018160896A1
(en)
|
2017-03-02 |
2018-09-07 |
Beth Israel Deaconess Medical Center |
Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
|
BR112019018043A2
(pt)
|
2017-03-03 |
2020-04-07 |
Seattle Genetics Inc |
método de tratamento de câncer, e, conjugado de anticorpo-fármaco
|
CA3056227A1
(en)
|
2017-03-13 |
2018-09-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for selective elimination and replacement of hematopoietic stem cells
|
BR112019019706A2
(pt)
|
2017-03-22 |
2020-04-28 |
Genentech Inc |
conjugado de anticorpo, anticorpo, composição farmacêutica, métodos para reduzir ou inibir angiogênese e para tratar um distúrbio ocular
|
CA3055985A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
JP2020514394A
(ja)
|
2017-03-24 |
2020-05-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
異常な線維芽細胞におけるプロテオグリカンの不規則性及びそれに基づく治療法
|
KR20190133723A
(ko)
|
2017-03-27 |
2019-12-03 |
에프. 호프만-라 로슈 아게 |
개선된 항원 결합 수용체
|
CR20190431A
(es)
|
2017-03-27 |
2019-11-01 |
Hoffmann La Roche |
Formatos mejorados de receptor de unión a antígeno
|
EP3606947B1
(de)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunokonjugat von il-2 mit einem bispezifischen antikörper gerichtet gegen pd-1 und tim-3
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
RU2019134462A
(ru)
|
2017-04-03 |
2021-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Антитела, связывающиеся с steap-1
|
CN117003887A
(zh)
|
2017-04-03 |
2023-11-07 |
豪夫迈·罗氏有限公司 |
抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
|
IL268620B2
(en)
|
2017-04-05 |
2024-04-01 |
Hoffmann La Roche |
Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
|
JP2020513019A
(ja)
|
2017-04-05 |
2020-04-30 |
ノヴォ ノルディスク アー/エス |
オリゴマー伸長インスリン−Fcコンジュゲート
|
BR112019019821A2
(pt)
|
2017-04-05 |
2020-04-22 |
Hoffmann La Roche |
anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
|
CA3059542A1
(en)
|
2017-04-12 |
2018-10-18 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
CA3058541A1
(en)
|
2017-04-14 |
2018-10-18 |
Gamamabs Pharma |
Amhrii-binding compounds for preventing or treating lung cancers
|
EP3609918A1
(de)
|
2017-04-14 |
2020-02-19 |
Gamamabs Pharma |
Amhrii-bindende verbindungen zur vorbeugung oder behandlung von krebs
|
BR112019021612A2
(pt)
|
2017-04-15 |
2020-05-12 |
Abbott Laboratories |
Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
|
EP3612563A1
(de)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle und verwendungen davon
|
EP3612560A1
(de)
|
2017-04-21 |
2020-02-26 |
Staten Biotechnology B.V. |
Anti-apoc3-antikörper und verfahren zur verwendung davon
|
WO2018195472A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
GB201706451D0
(en)
|
2017-04-24 |
2017-06-07 |
Imp Innovations Ltd |
Cancer treatment
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
CN110741019A
(zh)
|
2017-04-26 |
2020-01-31 |
优瑞科生物技术公司 |
特异性识别磷脂酰肌醇蛋白聚糖3的构筑体及其用途
|
WO2018200583A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
|
EP3615572A1
(de)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Gegen lymphozytenaktivierungsgen 3 (lag-3) gerichtete antikörpermittel und verwendungen davon
|
US10877038B2
(en)
|
2017-04-28 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
US20200385472A1
(en)
|
2017-04-28 |
2020-12-10 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
CA3062061A1
(en)
|
2017-05-01 |
2018-11-08 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) |
新的cd73抗体、其制备和用途
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
AU2018275235A1
(en)
|
2017-05-30 |
2019-10-31 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
JP2020522512A
(ja)
|
2017-05-31 |
2020-07-30 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
|
CN111148762A
(zh)
|
2017-05-31 |
2020-05-12 |
斯特库伯株式会社 |
免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
|
WO2018220584A1
(en)
|
2017-06-02 |
2018-12-06 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
MX2019013923A
(es)
|
2017-06-02 |
2020-01-21 |
Pfizer |
Receptores de antigenos quimericos que se dirigen a flt3.
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
CA3061959A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
JP2020525434A
(ja)
|
2017-06-22 |
2020-08-27 |
ムーンショット ファーマ エルエルシー |
アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
|
EP3642240A1
(de)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antikörpermoleküle gegen cd73 und verwendungen davon
|
EP3645042A4
(de)
|
2017-06-26 |
2021-03-17 |
Bio-Techne Corporation |
Hybridom-klone, monoklonale antikörper gegen vsig-4 und verfahren zur herstellung und verwendung
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
|
US11447809B2
(en)
|
2017-07-06 |
2022-09-20 |
President And Fellows Of Harvard College |
Evolution of tRNA synthetases
|
TWI820031B
(zh)
|
2017-07-11 |
2023-11-01 |
美商坎伯斯治療有限責任公司 |
結合人類cd137之促效劑抗體及其用途
|
CR20200076A
(es)
|
2017-07-14 |
2020-06-10 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
US11827669B2
(en)
|
2017-07-19 |
2023-11-28 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
EP3431496A1
(de)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗lag−3抗体の投薬量レジメンおよびその使用
|
WO2019018647A1
(en)
|
2017-07-20 |
2019-01-24 |
Pfizer Inc. |
ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3658583A1
(de)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
|
AU2018310985A1
(en)
|
2017-08-03 |
2019-11-07 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
SI3661954T1
(sl)
|
2017-08-03 |
2022-05-31 |
Amgen Inc. |
Muteini interlevkina-21 in postopki zdravljenja
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
MX2020002076A
(es)
|
2017-08-25 |
2020-03-24 |
Five Prime Therapeutics Inc |
Anticuerpos de b7-h4 y metodos para usarlos.
|
US20210130845A1
(en)
|
2017-09-08 |
2021-05-06 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
WO2019056002A1
(en)
|
2017-09-18 |
2019-03-21 |
President And Fellows Of Harvard College |
CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
TW201936634A
(zh)
|
2017-09-29 |
2019-09-16 |
日商中外製藥股份有限公司 |
具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
|
SG11202002248TA
(en)
|
2017-10-02 |
2020-04-29 |
Visterra Inc |
Antibody molecules to cd138 and uses thereof
|
EP3461841B1
(de)
|
2017-10-02 |
2019-09-11 |
Certest Biotec, S.L. |
Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
|
EP3692370A2
(de)
|
2017-10-04 |
2020-08-12 |
OPKO Pharmaceuticals, LLC |
Artikel und verfahren zur personalisierten krebstherapie
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
MX2020004074A
(es)
|
2017-10-19 |
2020-10-16 |
Debiopharm Int Sa |
Producto de combinacion para el tratamiento de cancer.
|
EP3697809A1
(de)
|
2017-10-20 |
2020-08-26 |
Institut Curie |
Für rush angepasste dap10/12-basierte cars
|
KR20200094147A
(ko)
|
2017-10-31 |
2020-08-06 |
알로젠 테라퓨틱스 인코포레이티드 |
동종이계 키메라 항원 수용체 t 세포를 투여하기 위한 방법 및 조성물
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
PL3704146T3
(pl)
|
2017-11-01 |
2022-03-07 |
F. Hoffmann-La Roche Ag |
Przeciwciało Contorsbody trifab
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
MX2020005562A
(es)
|
2017-11-30 |
2020-08-20 |
Genentech Inc |
Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.
|
EP3720881A1
(de)
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispezifische moleküle und verwendungen davon
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
AU2018378084A1
(en)
|
2017-12-09 |
2020-05-14 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
WO2019126133A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals, Inc. |
Liquid formulations of anti-cd200 antibodies
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
TWI805665B
(zh)
|
2017-12-21 |
2023-06-21 |
瑞士商赫孚孟拉羅股份公司 |
結合hla-a2/wt1之抗體
|
EP3729080B1
(de)
|
2017-12-21 |
2023-04-19 |
F. Hoffmann-La Roche AG |
Universelles reporterzellenassay zur spezifitätsprüfung von neuartigen antigenbindenden resten
|
WO2019122060A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Car-t cell assay for specificity test of novel antigen binding moieties
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
JP7391868B2
(ja)
|
2017-12-22 |
2023-12-05 |
ジョウンセ セラピューティクス, インク. |
Lilrb2に対する抗体
|
WO2019129221A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
TW201930350A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
EP3732193A1
(de)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b-antikörper und verfahren zu ihrer verwendung
|
CA3084370A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
BR112020014121A2
(pt)
|
2018-01-12 |
2020-12-01 |
Amgen Inc. |
anticorpos anti-pd-1 e métodos de tratamento
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
CN111971301A
(zh)
|
2018-01-31 |
2020-11-20 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
US11377500B2
(en)
|
2018-02-01 |
2022-07-05 |
Pfizer Inc. |
Antibodies specific for CD70 and their uses
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
US11787857B2
(en)
|
2018-02-02 |
2023-10-17 |
Bio-Techne Corporation |
Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
|
WO2019157131A1
(en)
|
2018-02-07 |
2019-08-15 |
Dana-Farber Cancer Institute, Inc. |
Cell-permeable stapled peptide modules for cellular delivery
|
AU2019218959A1
(en)
|
2018-02-08 |
2020-09-03 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
MA51741A
(fr)
|
2018-02-09 |
2021-05-19 |
Hoffmann La Roche |
Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
|
BR112020016400A2
(pt)
|
2018-02-14 |
2020-12-15 |
Viela Bio, Inc. |
Anticorpos para o ligante do receptor de tirosina cinase 3 similar ao sarcoma felino de mcdonough (fms) (flt3l) e suas utilizações para o tratamento de doenças autoimunes e inflamatórias
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
EP3759491A1
(de)
|
2018-03-01 |
2021-01-06 |
H. Hoffnabb-La Roche Ag |
Spezifizitätstests für neuartige zielantigenbindende gruppen
|
EP3759142A1
(de)
|
2018-03-02 |
2021-01-06 |
Five Prime Therapeutics, Inc. |
B7-h4-antikörper und verfahren zur verwendung davon
|
IL310216A
(en)
|
2018-03-05 |
2024-03-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
CA3093772A1
(en)
|
2018-03-12 |
2019-09-19 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
MX2021015518A
(es)
|
2018-03-14 |
2022-07-21 |
Surface Oncology Inc |
Anticuerpos que se unen a cd39 y sus usos.
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
US11332524B2
(en)
|
2018-03-22 |
2022-05-17 |
Surface Oncology, Inc. |
Anti-IL-27 antibodies and uses thereof
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
AU2019246007A1
(en)
|
2018-03-26 |
2020-09-10 |
Glycanostics S.R.O. |
Means and methods for glycoprofiling of a protein
|
JP7331000B2
(ja)
|
2018-03-26 |
2023-08-22 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体c3転換酵素のプロテアーゼ活性を測定するためのスループットの高い方法
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
WO2019192973A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
WO2019192972A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
US20210230255A1
(en)
|
2018-04-27 |
2021-07-29 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
EP3787678A1
(de)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Monoklonale neuraminidase-antikörper gegen influenza und ihre verwendungen
|
MA52590A
(fr)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
AU2019264712A1
(en)
|
2018-05-11 |
2021-01-07 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Fully human antibodies against OX40, method for preparing same, and use thereof
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
MX2020012607A
(es)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos.
|
MX2020012539A
(es)
|
2018-05-23 |
2021-02-16 |
Pfizer |
Anticuerpos especificos para cd3 y sus usos.
|
AR115418A1
(es)
|
2018-05-25 |
2021-01-13 |
Alector Llc |
ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US11913044B2
(en)
|
2018-06-14 |
2024-02-27 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
US11830582B2
(en)
|
2018-06-14 |
2023-11-28 |
University Of Miami |
Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
|
CN112533632A
(zh)
|
2018-06-18 |
2021-03-19 |
Ucb生物制药有限责任公司 |
用于预防和治疗癌症的gremlin-1拮抗剂
|
JP7097465B2
(ja)
|
2018-06-19 |
2022-07-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
|
US20210238268A1
(en)
|
2018-06-19 |
2021-08-05 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
MA52968A
(fr)
|
2018-06-23 |
2021-04-28 |
Hoffmann La Roche |
Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
SG11202010990TA
(en)
|
2018-06-29 |
2020-12-30 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
HRP20212034T1
(hr)
|
2018-07-11 |
2022-04-01 |
Scholar Rock, Inc. |
Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
|
AU2019302679A1
(en)
|
2018-07-11 |
2021-02-11 |
Scholar Rock, Inc. |
High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof
|
US20210340238A1
(en)
|
2018-07-11 |
2021-11-04 |
Scholar Rock, Inc. |
TGFß1 INHIBITORS AND USE THEREOF
|
PE20210186A1
(es)
|
2018-07-13 |
2021-02-02 |
Alector Llc |
Anticuerpos anti-sortilina y metodos para su uso
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
WO2020016838A2
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained response predictors after treatment with anti-il23 specific antibody
|
JP2021531007A
(ja)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Vistaに対する受容体
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
AU2019316556B9
(en)
|
2018-08-08 |
2024-01-04 |
Pml Screening, Llc |
Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
|
KR20210042936A
(ko)
|
2018-08-08 |
2021-04-20 |
제넨테크, 인크. |
단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도
|
EP3833443A1
(de)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigenbindende mittel, die cd277 binden, und verwendungen davon
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
BR112021002487A2
(pt)
|
2018-08-10 |
2021-07-27 |
Eutilex Co., Ltd. |
receptor de antígeno quimérico que se liga a hla-dr e célula car-t
|
EA202190451A1
(ru)
|
2018-08-10 |
2021-07-13 |
Чугаи Сейяку Кабусики Кайся |
Анти-cd137 антигенсвязывающие молекулы и их применение
|
US11548938B2
(en)
|
2018-08-21 |
2023-01-10 |
Quidel Corporation |
DbpA antibodies and uses thereof
|
SG11202101552SA
(en)
|
2018-08-31 |
2021-03-30 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
US10899826B1
(en)
|
2018-09-13 |
2021-01-26 |
Teva Pharmaceuticals International Gmbh |
Pharmaceutical compositions for an anti-CGRP antagonist antibody
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP3857230B1
(de)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnosemethoden für dreifach-negativen brustkrebs
|
LT3883606T
(lt)
|
2018-09-24 |
2023-09-11 |
Janssen Biotech, Inc. |
Saugus ir veiksmingas opinio kolito gydymo būdas anti-il12/il23 antikūnu
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
CA3114295A1
(en)
|
2018-09-28 |
2020-04-02 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
CA3113818A1
(en)
|
2018-10-05 |
2020-04-09 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
JP7289913B2
(ja)
|
2018-10-11 |
2023-06-12 |
ファイザー・インク |
Tfpiアンタゴニストのための投薬レジメン
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
CA3117561A1
(en)
|
2018-10-23 |
2020-04-30 |
Samantha NICHOLLS |
Rgmc-selective inhibitors and use thereof
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
KR20210090645A
(ko)
|
2018-11-05 |
2021-07-20 |
제넨테크, 인크. |
원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
|
AU2019380320A1
(en)
|
2018-11-16 |
2021-06-03 |
Eureka Therapeutics, Inc. |
Antibodies to Mucin-16 and methods of use thereof
|
EP3883961A1
(de)
|
2018-11-20 |
2021-09-29 |
Takeda Vaccines, Inc. |
Neuartige zika-virus-antikörper und ihre verwendungen
|
BR112021009856A8
(pt)
|
2018-11-20 |
2021-09-08 |
Bavarian Nordic As |
Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
EP3894427A1
(de)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
JP2022513255A
(ja)
|
2018-12-20 |
2022-02-07 |
ノバルティス アーゲー |
HDM2-p53相互作用阻害剤とBCL2阻害剤との組み合わせ及び癌を処置するためのその使用
|
EP3883609A2
(de)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Glykoprotein-spezifische monoklonale antikörper des ebola-virus und deren verwendungen
|
WO2020132396A1
(en)
|
2018-12-20 |
2020-06-25 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
AU2019402163A1
(en)
|
2018-12-20 |
2021-07-08 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
PE20211294A1
(es)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
Anticuerpo que se une a vegf y a il-1beta y metodos de utilizacion
|
WO2020132231A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
JP2022515473A
(ja)
|
2018-12-28 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質
|
US11447551B2
(en)
|
2018-12-28 |
2022-09-20 |
Sparx Bioscience Limited |
Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
|
KR20210116540A
(ko)
|
2019-01-15 |
2021-09-27 |
얀센 바이오테크 인코포레이티드 |
소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
|
AU2020208397A1
(en)
|
2019-01-16 |
2021-08-12 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human CD137 and uses thereof
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
MX2021008561A
(es)
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
CA3126727A1
(en)
|
2019-01-28 |
2020-08-06 |
Maple Biotech Llc |
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
TW202043267A
(zh)
|
2019-01-30 |
2020-12-01 |
美商供石公司 |
TGFβ之LTBP複合物專一性抑制劑及其用途
|
US11738050B2
(en)
|
2019-02-01 |
2023-08-29 |
Regents Of The University Of Minnesota |
Compounds binding to fibroblast activation protein alpha
|
EP3693063A1
(de)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Verfahren und zusammensetzungen zur behandlung von krebs
|
EP3696191A1
(de)
|
2019-02-14 |
2020-08-19 |
Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) |
Car-t-zellen zur behandlung von cd1a-positivem krebs
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020172571A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
AU2020224680A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
CN114127111A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
EA202192505A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
US20200331996A1
(en)
|
2019-03-18 |
2020-10-22 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
EP3948289A1
(de)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Modulatoren von zelloberflächenproteininteraktionen und verfahren sowie zusammensetzungen damit
|
MA55519A
(fr)
|
2019-03-29 |
2022-02-09 |
Atarga Llc |
Anticorps anti-fgf23
|
JPWO2020213724A1
(de)
|
2019-04-19 |
2020-10-22 |
|
|
CA3134522A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
EP3962523A2
(de)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen das plasmodium-falciparum-circumsporozoit-protein und verwendung davon
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
WO2020234834A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Cdk阻害剤を使用した組合せ療法
|
EP3976183A1
(de)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver ankylosierender spondylitis
|
MX2021014885A
(es)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech Inc |
Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica.
|
US20200392229A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
WO2020257289A2
(en)
|
2019-06-17 |
2020-12-24 |
Visterra, Inc. |
Humanized antibody molecules to cd138 and uses thereof
|
TW202115115A
(zh)
|
2019-07-02 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫結合物
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
WO2021014389A1
(en)
|
2019-07-24 |
2021-01-28 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
CA3147757A1
(en)
|
2019-07-26 |
2021-02-04 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
BR112022001460A2
(pt)
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
US11667699B2
(en)
|
2019-07-31 |
2023-06-06 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
FI4007777T3
(fi)
|
2019-08-02 |
2024-01-11 |
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap |
CAR-T-soluja B-solujen kypsymisantigeeniä (BCMA) vastaan multippelin myelooman hoitoon
|
JP7181438B2
(ja)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
病理学的タウ種に結合する抗体及びその使用
|
EP4031658A1
(de)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Verbesserte meerrettichperoxidase-polypeptide
|
AU2020329217A1
(en)
|
2019-08-12 |
2022-07-28 |
Aptevo Research And Development Llc |
4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CR20220076A
(es)
|
2019-08-30 |
2022-06-24 |
Agenus Inc |
Anticuerpos anti-cd96 y sus métodos de uso
|
US20220332799A1
(en)
|
2019-09-04 |
2022-10-20 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Herv inhibitors for use in treating tauopathies
|
AU2020342910A1
(en)
|
2019-09-04 |
2022-04-07 |
Pierre Fabre Medicament |
Anti-VSIG4 antibody or antigen binding fragment and uses thereof
|
EP4025593A1
(de)
|
2019-09-05 |
2022-07-13 |
Poseida Therapeutics, Inc. |
Zusammensetzungen allogener zellen und verfahren zur verwendung
|
KR20220062304A
(ko)
|
2019-09-12 |
2022-05-16 |
제넨테크, 인크. |
루푸스 신장염을 치료하는 조성물과 방법
|
WO2021055329A1
(en)
|
2019-09-16 |
2021-03-25 |
Surface Oncology, Inc. |
Anti-cd39 antibody compositions and methods
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
EP4031578A1
(de)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
|
EP4031579A2
(de)
|
2019-09-18 |
2022-07-27 |
F. Hoffmann-La Roche AG |
Anti-klk7-antikörper, anti-klk5-antikörper, multispezifische anti-klk5-klk7-antikörper und verwendungsverfahren
|
US20220348687A1
(en)
|
2019-09-20 |
2022-11-03 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
CN114729045A
(zh)
|
2019-09-26 |
2022-07-08 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
EP4036116A4
(de)
|
2019-09-27 |
2024-01-24 |
Nanjing Genscript Biotech Co Ltd |
Anti-vhh-domänen-antikörper und verwendung davon
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
JP2022553306A
(ja)
|
2019-10-21 |
2022-12-22 |
ノバルティス アーゲー |
Tim-3阻害剤およびその使用
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
MX2022005400A
(es)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
|
CA3159588A1
(en)
|
2019-11-20 |
2021-05-27 |
Bavarian Nordic A/S |
Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
CR20220329A
(es)
|
2019-12-13 |
2022-11-23 |
Alector Llc |
Anticuerpos anti–mertk y metodos de uso de los mismos
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
CA3161390A1
(en)
|
2019-12-18 |
2021-06-24 |
Tina WEINZIERL |
Antibodies binding to hla-a2/mage-a4
|
CN115298213A
(zh)
|
2019-12-19 |
2022-11-04 |
奎多公司 |
单克隆抗体融合
|
CN115135672A
(zh)
|
2019-12-20 |
2022-09-30 |
波赛达治疗公司 |
抗muc1组合物和使用方法
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
IL294226A
(en)
|
2019-12-27 |
2022-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibodies and their use
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4084821A4
(de)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics Inc |
An cd33 bindende multifunktionsmoleküle und ihre verwendungen
|
WO2021142002A1
(en)
|
2020-01-06 |
2021-07-15 |
Vaccinex, Inc. |
Anti-ccr8 antibodies and uses thereof
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
CA3167427A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Tgfb inhibitors and use thereof
|
CA3166328A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
WO2021146487A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
CA3167413A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
EP4105237A4
(de)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co Ltd |
Cldn18.2-antikörper und verwendung davon
|
US20230096452A1
(en)
|
2020-02-10 |
2023-03-30 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
WO2021160269A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
WO2021160268A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
WO2021160266A1
(en)
|
2020-02-13 |
2021-08-19 |
UCB Biopharma SRL |
Bispecific antibodies binding hvem and cd9
|
US20230151108A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
EP4103609A1
(de)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispezifische antikörper gegen cd9 und cd7
|
US11692038B2
(en)
|
2020-02-14 |
2023-07-04 |
Gilead Sciences, Inc. |
Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
|
EP4106788A1
(de)
|
2020-02-18 |
2022-12-28 |
Alector LLC |
Pilra-antikörper und verfahren zur verwendung davon
|
WO2021170067A1
(zh)
|
2020-02-28 |
2021-09-02 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体及其用途
|
EP4110826A1
(de)
|
2020-02-28 |
2023-01-04 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137-konstrukte, multispezifischer antikörper und dessen verwendungen
|
US20230235073A1
(en)
|
2020-03-06 |
2023-07-27 |
Ona Therapeutics, S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
EP4118107A1
(de)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimäre stimulationsrezeptoren und verfahren zur verwendung bei der t-zell-aktivierung und -differenzierung
|
MX2022011289A
(es)
|
2020-03-11 |
2022-12-08 |
Fundacio Inst De Recerca Contra La Leucemia Josep Carreras |
Porcion de direccionamiento a cd22 para el tratamiento de leucemia linfoblastica aguda de celulas b (b-all).
|
MX2022011156A
(es)
|
2020-03-13 |
2022-10-13 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos.
|
US11919948B2
(en)
|
2020-03-19 |
2024-03-05 |
Genentech, Inc. |
Isoform-selective anti-TGFβ antibodies and methods of use
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
EP4126940A1
(de)
|
2020-03-30 |
2023-02-08 |
F. Hoffmann-La Roche AG |
An vegf und pdgf-b bindender antikörper und verfahren zur verwendung
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
EP4126937A1
(de)
|
2020-03-31 |
2023-02-08 |
Alector LLC |
Anti-mertk-antikörper und verfahren zur verwendung davon
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
CA3178465A1
(en)
|
2020-04-03 |
2021-10-07 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
KR20230011295A
(ko)
|
2020-04-14 |
2023-01-20 |
포세이다 테라퓨틱스, 인크. |
암 치료에 사용하기 위한 조성물 및 방법
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
TW202216757A
(zh)
|
2020-04-28 |
2022-05-01 |
美國洛克菲勒大學 |
中和性抗sars-cov-2抗體及其使用方法
|
BR112022022021A2
(pt)
|
2020-04-30 |
2022-12-13 |
Genentech Inc |
Anticorpos, ácido(s) nucleico(s), vetor, célula hospedeira, processo para produzir um anticorpo, métodos para rastrear um anticorpo, detectar kras-gdp, obter um inibidor, detectar a alquilação de kras, tratar um câncer, rastrear compostos, medir a ligação de uma proteína e medir o engajamento do alvo de um inibidor, kit, chaperona de cristalização, método de cristalização e superfície de biossensor
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
CA3177562A1
(en)
|
2020-05-03 |
2021-11-11 |
Tong Zhu |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
WO2021226290A1
(en)
|
2020-05-05 |
2021-11-11 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
AU2021275361A1
(en)
|
2020-05-17 |
2023-01-19 |
Astrazeneca Uk Limited |
SARS-CoV-2 antibodies and methods of selecting and using the same
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
CN113993900B
(zh)
|
2020-05-27 |
2023-08-04 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别神经生长因子的抗体及其用途
|
EP4158058A1
(de)
|
2020-06-02 |
2023-04-05 |
10X Genomics, Inc. |
Anreicherung von nukleinsäuresequenzen
|
IL298735A
(en)
|
2020-06-02 |
2023-02-01 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and their uses
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
TW202204396A
(zh)
|
2020-06-08 |
2022-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗hbv抗體及使用方法
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
TW202200616A
(zh)
|
2020-06-18 |
2022-01-01 |
美商建南德克公司 |
使用抗tigit抗體及pd-1軸結合拮抗劑之治療
|
MX2022016591A
(es)
|
2020-06-24 |
2023-04-20 |
Visterra Inc |
Moléculas de anticuerpo contra april y usos de las mismas.
|
EP4178624A2
(de)
|
2020-07-07 |
2023-05-17 |
Bionecure Therapeutics, Inc. |
Maytansinoide als adc-nutzlasten und deren verwendung zur behandlung von krebs
|
AR123001A1
(es)
|
2020-07-17 |
2022-10-19 |
Genentech Inc |
Anticuerpos anti-notch2 y métodos de uso
|
EP4182346A1
(de)
|
2020-07-17 |
2023-05-24 |
Pfizer Inc. |
Therapeutische antikörper und deren verwendungen
|
AU2021313348A1
(en)
|
2020-07-20 |
2023-03-09 |
Astrazeneca Uk Limited |
SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies, and methods of using the same
|
CN116194488A
(zh)
|
2020-07-21 |
2023-05-30 |
艾洛基治疗公司 |
具有增强的信号传导和活性的嵌合抗原受体和其用途
|
CN116249556A
(zh)
|
2020-07-21 |
2023-06-09 |
基因泰克公司 |
降解brm的抗体缀合化学诱导剂及其方法
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
AU2021315665A1
(en)
|
2020-07-29 |
2023-03-16 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
CA3188349A1
(en)
|
2020-08-04 |
2022-02-10 |
A. Scott Muerhoff |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
AU2021328375A1
(en)
|
2020-08-18 |
2023-04-13 |
Cephalon Llc |
Anti-PAR-2 antibodies and methods of use thereof
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
EP4204096A2
(de)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
An nkp30 bindende antikörpermoleküle und verwendungen davon
|
EP4204020A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
EP4204021A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
BR112023004415A2
(pt)
|
2020-09-11 |
2023-05-09 |
Medimmune Ltd |
Moléculas terapêuticas de ligação a b7-h4
|
KR20230066095A
(ko)
|
2020-09-12 |
2023-05-12 |
메디뮨 리미티드 |
항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
|
EP3981789A1
(de)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb-antikörper und verwendungen davon
|
EP4228764A1
(de)
|
2020-10-14 |
2023-08-23 |
Five Prime Therapeutics, Inc. |
Anti-c-chemokinrezeptor-8-(ccr8)-antikörper und verfahren zur verwendung davon
|
EP4229081A1
(de)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
|
EP4229086A1
(de)
|
2020-10-15 |
2023-08-23 |
UCB Biopharma SRL |
Bindungsmoleküle, die cd45 multimerisieren
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022090181A1
(en)
|
2020-10-28 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
EP4240493A2
(de)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosierung zur behandlung mit bispezifischen anti-cd20/anti-cd3-antikörpern und anti-cd79b-antikörper-wirkstoffkonjugaten
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
EP4251647A1
(de)
|
2020-11-24 |
2023-10-04 |
Bio-Techne Corporation |
Anti-sever-antikörper des akuten atemwegssyndroms coronavirus
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CA3200314A1
(en)
|
2020-12-01 |
2022-06-09 |
Peter Pavlik |
Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
TW202237171A
(zh)
|
2020-12-04 |
2022-10-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
US20240067758A1
(en)
|
2020-12-07 |
2024-02-29 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
WO2022122652A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
CA3202339A1
(en)
|
2020-12-18 |
2022-06-23 |
Mei Jang |
Protein compositions and methods for producing and using the same
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ, インコーポレイテッド |
高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2022153194A1
(en)
|
2021-01-13 |
2022-07-21 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
KR20230146522A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항-dll3 항체-약물 접합체
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
TW202245825A
(zh)
|
2021-01-20 |
2022-12-01 |
美商威特拉公司 |
介白素-2藥劑及其用途
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
WO2022173689A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
JP2024509165A
(ja)
|
2021-03-02 |
2024-02-29 |
シージーアールピー ダイアグノスティクス ゲーエムベーハー |
片頭痛の治療及び/又は発生の低減
|
US20240041978A1
(en)
|
2021-03-03 |
2024-02-08 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
La protein as a novel regulator of osteoclastogenesis
|
EP4301418A1
(de)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antikörper-wirkstoff-konjugate mit einem anti-bcma-antikörper
|
EP4301786A1
(de)
|
2021-03-03 |
2024-01-10 |
Pierre Fabre Medicament |
Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
|
EP4301472A1
(de)
|
2021-03-05 |
2024-01-10 |
Dynamicure Biotechnology LLC |
Anti-vista-konstrukte und verwendungen davon
|
KR20230156764A
(ko)
|
2021-03-12 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
JP2024511970A
(ja)
|
2021-03-15 |
2024-03-18 |
ジェネンテック, インコーポレイテッド |
ループス腎炎の治療の組成物及び方法
|
CN116981696A
(zh)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
WO2022195028A2
(en)
|
2021-03-18 |
2022-09-22 |
Medimmune Limited |
Therapeutic binding molecules
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗tmem106b抗体
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
EP4067381A1
(de)
|
2021-04-01 |
2022-10-05 |
Julius-Maximilians-Universität Würzburg |
Neue tnfr2-bindende moleküle
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
EP4330282A1
(de)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosierung für kombinationsbehandlung mit bispezifischem anti-cd20/anti-cd3-antikörper und anti-cd79b-antikörper-wirkstoffkonjugat
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
CN117642428A
(zh)
|
2021-05-03 |
2024-03-01 |
Ucb生物制药有限责任公司 |
抗体
|
EP4334343A2
(de)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
|
KR20240005809A
(ko)
|
2021-05-07 |
2024-01-12 |
서피스 온콜로지, 엘엘씨 |
항-il-27 항체 및 이의 용도
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
AU2022279156A1
(en)
|
2021-05-18 |
2023-11-02 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
CA3220629A1
(en)
|
2021-05-28 |
2022-12-01 |
Tobin J. CAMMETT |
Methods for detecting cm-tma biomarkers
|
WO2022256313A1
(en)
|
2021-06-01 |
2022-12-08 |
10X Genomics, Inc. |
Validation of a unique molecular identifier associated with a nucleic acid sequence of interest
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
EP4155321A1
(de)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2-antikörper und verwendungen davon
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
KR20240019109A
(ko)
|
2021-06-09 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
암의 치료에 이용하기 위한 특정 braf 억제제(패러독스 브레이크) 및 pd-1 축 결합 길항제의 조합물
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
EP4355783A1
(de)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalente anti-mertk-antikörper und verfahren zur verwendung davon
|
EP4355785A1
(de)
|
2021-06-17 |
2024-04-24 |
Amberstone Biosciences, Inc. |
Anti-cd3-konstrukte und verwendungen davon
|
IL309078A
(en)
|
2021-06-23 |
2024-02-01 |
Scholar Rock Inc |
A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
|
WO2022270612A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ctla-4抗体の使用
|
KR20240024213A
(ko)
|
2021-06-25 |
2024-02-23 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法
|
WO2023283611A1
(en)
|
2021-07-08 |
2023-01-12 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
US20230040065A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
US20230042465A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
US20230038355A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
AU2022320051A1
(en)
|
2021-07-30 |
2024-01-25 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
WO2023012343A1
(en)
|
2021-08-06 |
2023-02-09 |
Institut Du Cancer De Montpellier |
Methods for the treatment of cancer
|
IL310535A
(en)
|
2021-08-10 |
2024-03-01 |
Byomass Inc |
Anti-GDF15 antibodies, compositions and uses thereof
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
WO2023026205A1
(en)
|
2021-08-24 |
2023-03-02 |
Cgrp Diagnostics Gmbh |
Preventative treatment of migraine
|
WO2023025927A1
(en)
|
2021-08-26 |
2023-03-02 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023032955A1
(ja)
|
2021-08-31 |
2023-03-09 |
大正製薬株式会社 |
抗成長ホルモン抗体
|
CA3230815A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long ot syndrome
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
AU2022360244A1
(en)
|
2021-10-04 |
2024-04-11 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
WO2023058705A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
抗hla-dq2.5抗体の製剤
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
CA3234731A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
EP4177266A1
(de)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralisierende humane anti-sars-cov-2-antikörper
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023086824A1
(en)
|
2021-11-10 |
2023-05-19 |
10X Genomics, Inc. |
Methods for identification of antigen-binding molecules
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
US20230348614A1
(en)
|
2021-11-24 |
2023-11-02 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
WO2023141576A1
(en)
|
2022-01-21 |
2023-07-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acids
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
TW202346365A
(zh)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及化學療法之組合治療
|
WO2023180511A1
(en)
|
2022-03-25 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Improved chimeric receptors
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
WO2023192436A1
(en)
|
2022-03-31 |
2023-10-05 |
Alexion Pharmaceuticals, Inc. |
Singleplex or multiplexed assay for complement markers in fresh biological samples
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
WO2023196866A1
(en)
|
2022-04-06 |
2023-10-12 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023212518A1
(en)
|
2022-04-25 |
2023-11-02 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023250402A2
(en)
|
2022-06-22 |
2023-12-28 |
Antlera Therapeutics Inc. |
Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
|
EP4296279A1
(de)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024050354A1
(en)
|
2022-08-31 |
2024-03-07 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024062038A1
(en)
|
2022-09-21 |
2024-03-28 |
Elthera Ag |
Novel binding molecules binding to l1cam
|